<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680139</article-id><article-id pub-id-type="doi">10.3390/v16121884</article-id><article-id pub-id-type="publisher-id">viruses-16-01884</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Antiviral Stewardship in Transplantation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bonda</surname><given-names>Sruthi</given-names></name><xref rid="af1-viruses-16-01884" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Trinh</surname><given-names>Sonya</given-names></name><xref rid="af1-viruses-16-01884" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Hand</surname><given-names>Jonathan</given-names></name><xref rid="af1-viruses-16-01884" ref-type="aff">1</xref><xref rid="af2-viruses-16-01884" ref-type="aff">2</xref><xref rid="c1-viruses-16-01884" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ho</surname><given-names>Dora</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Tayyar</surname><given-names>Ralph</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01884"><label>1</label>Department of Infectious Diseases, Ochsner Medical Center, New Orleans, LA 70115, USA</aff><aff id="af2-viruses-16-01884"><label>2</label>Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, LA 70115, USA</aff><author-notes><corresp id="c1-viruses-16-01884"><label>*</label>Correspondence: <email>jonathan.hand@ochsner.org</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1884</elocation-id><history><date date-type="received"><day>01</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>29</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>04</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Though antimicrobial stewardship programs (ASPs) are required for hospitals, the involvement of transplant recipients in programmatic interventions, protocols, and metrics has historically been limited. Though there is a growing interest in studying stewardship practices in transplant patients, optimal practices have not been clearly established. A component of ASPs, antiviral stewardship (AVS), specifically targeting cytomegalovirus (CMV), has been more recently described. Understanding AVS opportunities and interventions is particularly important for transplant recipients, given the morbidity and mortality associated with viral infections, challenging clinical syndromes, ultrasensitive molecular diagnostic assays, antiviral resistance, and costs of viral disease and medications, as well as antiviral drug toxicities. This review highlights opportunities for AVS for CMV, EBV, HSV, VZV, SARS-CoV-2, respiratory syncytial virus, and BK polyomavirus in transplant patients.</p></abstract><kwd-group><kwd>antimicrobial stewardship</kwd><kwd>antiviral stewardship</kwd><kwd>cytomegalovirus</kwd><kwd>respiratory syncytial virus</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01884"><title>1. Introduction</title><p>Antimicrobial stewardship programs (ASPs) promote the appropriate use of antimicrobials with the goal of improving patient outcomes, decreasing unintended adverse effects, and reducing the development of multidrug-resistant organisms (MDROs). Among solid organ transplant (SOT) and hematopoietic-cell transplant (HCT) recipients, antimicrobial stewardship is critical to preserve the efficacy of antimicrobials given the increased risk of both severe and recurrent infections related to underlying immunosuppression. Furthermore, the appropriate use of antimicrobials is essential to avoid drug interactions with immunosuppressive agents and prevent adverse effects on bone marrow, organ, and graft function [<xref rid="B1-viruses-16-01884" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01884" ref-type="bibr">2</xref>].</p><p>Historically, ASPs have focused on inpatient settings to provide general guidance on targeted antimicrobial therapy for infections by organ system. This generalized approach is a challenge to apply to transplant recipients as each patient has a unique set of risk factors to consider, including history of colonization with MDROs, viral serostatus, timing since transplant, type of graft, and intensity and duration of immunosuppression. Transplant ASPs build on the goal of optimizing antimicrobial use in both the outpatient and inpatient settings to improve clinical outcomes and decrease unintended adverse effects while considering each patient&#x02019;s unique set of infectious risk factors [<xref rid="B1-viruses-16-01884" ref-type="bibr">1</xref>].</p><p>While ASPs have primarily addressed the appropriate use of antibacterial and antifungal agents, antiviral stewardship (AVS) in transplant recipients is a growing area of research [<xref rid="B3-viruses-16-01884" ref-type="bibr">3</xref>,<xref rid="B4-viruses-16-01884" ref-type="bibr">4</xref>]. Though less frequently problematic in immunocompetent patients, common viruses encountered after transplant include cytomegalovirus (CMV), Epstein&#x02013;Barr virus (EBV), herpes simplex virus (HSV), varicella-zoster virus (VZV), human-herpes virus 6, 7, 8 (HHV-6, HHV-7, HHV-8), and BK polyomavirus (BKPyV). Additionally, widespread community-acquired respiratory viruses such as influenza, respiratory syncytial virus (RSV), adenovirus (AdV), and SARS-CoV-2 may lead to significant morbidity and mortality in immunocompromised patients.</p><p>Unfortunately, data evaluating efficacy of antiviral treatment for many of the above viruses that impact transplant recipients are limited to underpowered, uncontrolled studies with heterogenous patient populations, and treatment recommendations are based on expert opinion [<xref rid="B5-viruses-16-01884" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01884" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01884" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01884" ref-type="bibr">8</xref>,<xref rid="B9-viruses-16-01884" ref-type="bibr">9</xref>]. Additionally, low-level viral replication and detection may not be associated with clinical disease or complications in some populations of transplant recipients (e.g., CMV, HHV-6, BKPyV). In many instances of low-level viral replication, these viruses do not need to be treated. However, the lack of validated viral detection thresholds and heterogeneity of net-immunosuppression across transplant populations (SOT/HCT) further increases the variability of practice.</p><p>Many available antivirals commonly used for these viruses may cause significant patient toxicity (ganciclovir, foscarnet, ribavirin, cidofovir). Moreover, prolonged use of valganciclovir/ganciclovir (vGCV/GCV) is associated with (val)ganciclovir-resistant CMV, and emergence of resistance to newer agents like maribavir and letermovir has been described [<xref rid="B10-viruses-16-01884" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01884" ref-type="bibr">11</xref>,<xref rid="B12-viruses-16-01884" ref-type="bibr">12</xref>,<xref rid="B13-viruses-16-01884" ref-type="bibr">13</xref>]. Furthermore, the overuse of antivirals may limit the development of viral-specific cell-mediated immunity leading to late-stage reactivation of viral infections in the setting of increased immunosuppression [<xref rid="B14-viruses-16-01884" ref-type="bibr">14</xref>].</p><p>Though lack of evidence and limited consensus guidance may lead to management challenges, antiviral drug toxicity, resistance concerns, cost, and the arrival new antivirals on the market make these agents and clinical syndromes prime targets for AVS programmatic interventions. This article will review opportunities to optimize, personalize, or avoid unnecessary antiviral therapy in SOT and HCT recipients focusing on CMV, EBV, HSV/VZV, SARS-CoV-2, RSV, and BKPyV. Though antivirals are recommended for influenza, opportunities for AVS are limited and will not be discussed.</p></sec><sec id="sec2-viruses-16-01884"><title>2. Antiviral Stewardship for Cytomegalovirus After Solid Organ Transplantation</title><p>Cytomegalovirus remains one the most common infections after SOT and HCT, with direct and indirect effects increasing the risk for other types of infections, impacting graft function, and is associated with significant morbidity and even mortality [<xref rid="B15-viruses-16-01884" ref-type="bibr">15</xref>]. Further, CMV continues to challenge patients and clinicians in the current era of prophylaxis, rapid molecular tests, and CMV-specific cell-mediated immunity (CMI) assays.</p><p>The most comprehensive CMV-specific stewardship program recently described by Jorgensen et al. was initiated amidst institutional concerns regarding CMV resistance, related hospital admissions, prolonged admissions, associated costs, graft outcomes, and antiviral toxicities [<xref rid="B3-viruses-16-01884" ref-type="bibr">3</xref>]. This program was modeled on traditional ASPs and was supported by a multidisciplinary group of clinicians from pharmacy, transplant ID, and abdominal transplant physicians and surgeons, and relied heavily on prospective audit and feedback [<xref rid="B4-viruses-16-01884" ref-type="bibr">4</xref>]. Consensus guidelines were created for prophylaxis and treatment agents, dosing and duration, and screening and diagnosis incorporating CMV cell-mediated immunity (CMI) testing to dictate the need for further surveillance. This CMV stewardship bundled intervention significantly decreased the valganciclovir days of therapy (DOT) as well as the rate of ganciclovir-resistant CMV over time [<xref rid="B3-viruses-16-01884" ref-type="bibr">3</xref>].</p><sec id="sec2dot1-viruses-16-01884"><title>2.1. CMV Prevention</title><p>Prophylaxis and pre-emptive therapy (PET) are acceptable CMV prevention strategies, with PET mostly utilized after HCT [<xref rid="B15-viruses-16-01884" ref-type="bibr">15</xref>]. However, centers may consider PET as a stewardship-concordant strategy in SOT, with recent data in high-risk liver transplant recipients supporting better CMV-specific outcomes, including CMV immunologic endpoints and 5-year survival [<xref rid="B16-viruses-16-01884" ref-type="bibr">16</xref>,<xref rid="B17-viruses-16-01884" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01884" ref-type="bibr">18</xref>].</p><p>Though historically vGCV has been the most widely used antiviral for primary CMV prophylaxis after SOT, a recent randomized, multicenter phase 3 trial evaluated kidney transplant recipients with high-risk CMV serostatus (D+/R&#x02212;), comparing primary prophylaxis with letermovir (with acyclovir) to vGCV, and found that letermovir was noninferior to vGCV, with lower rates of leukopenia and neutropenia [<xref rid="B19-viruses-16-01884" ref-type="bibr">19</xref>]. Real-world experience with letermovir primary prophylaxis in other SOT populations (e.g., heart, lung transplant) has been described in small retrospective studies and may be helpful in patients unable to obtain or tolerate vGCV [<xref rid="B20-viruses-16-01884" ref-type="bibr">20</xref>,<xref rid="B21-viruses-16-01884" ref-type="bibr">21</xref>]. The benefits of letermovir prophylaxis need to be weighed against other factors including cost, access, adverse effects, and drug interactions [<xref rid="B22-viruses-16-01884" ref-type="bibr">22</xref>,<xref rid="B23-viruses-16-01884" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01884" ref-type="bibr">24</xref>]. Reported adverse effects related to letermovir include nausea, vomiting, diarrhea, edema, and atrial fibrillation or flutter [<xref rid="B22-viruses-16-01884" ref-type="bibr">22</xref>,<xref rid="B25-viruses-16-01884" ref-type="bibr">25</xref>]. There are multiple drug interactions to consider when using letermovir as it decreases voriconazole and increases tacrolimus, sirolimus, and cyclosporine levels [<xref rid="B23-viruses-16-01884" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01884" ref-type="bibr">24</xref>]. Larger studies, including cost-effectiveness analyses, are needed to understand and refine ideal letermovir prophylactic strategies in SOT. Until more is understood, targeting inappropriate letermovir use may be an AVS opportunity for many transplant centers. Importantly, letermovir does not have activity against HSV or VZV, and prophylactic agents active against these viruses, e.g., (v)ACV, should be added if indicated.</p><p>Preventing CMV recurrence after therapy may be challenging in SOT recipients, and some centers routinely give secondary antiviral prophylaxis to all transplant recipients. Though no prospective, randomized trials have been carried out to evaluate the role of secondary prophylaxis to prevent CMV recurrence, multiple retrospective studies have demonstrated no benefit [<xref rid="B26-viruses-16-01884" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01884" ref-type="bibr">27</xref>,<xref rid="B28-viruses-16-01884" ref-type="bibr">28</xref>]. Further, national and international consensus guidelines recommend against the routine use of secondary prophylaxis for all patients [<xref rid="B15-viruses-16-01884" ref-type="bibr">15</xref>,<xref rid="B27-viruses-16-01884" ref-type="bibr">27</xref>]. These recommendations, combined with the potential antiviral toxicity, resistance, and cost, make secondary prophylaxis an ideal AVS target to address.</p></sec><sec id="sec2dot2-viruses-16-01884"><title>2.2. CMV Treatment</title><p>The currently available antiviral drugs for the treatment of CMV infection and disease are limited by numerous adverse effects. First-line therapy, vGCV, and GCV have unintended myelosuppressive effects, which is associated with poor outcomes in SOT [<xref rid="B29-viruses-16-01884" ref-type="bibr">29</xref>]. Furthermore, as their administration requires dose adjustments based on renal function, exposure to subtherapeutic levels leads to the development of drug-resistant CMV [<xref rid="B15-viruses-16-01884" ref-type="bibr">15</xref>]. Foscarnet is a recommended second-line agent for CMV treatment if patients are intolerant to vGCV/GCV, or it may be used for ganciclovir-resistant viruses. Lastly, cidofovir is associated with nephrotoxicity, electrolyte wasting, and neurotoxicity and should be avoided after SOT if possible [<xref rid="B30-viruses-16-01884" ref-type="bibr">30</xref>].</p><p>Maribavir, a UL97 protein kinase inhibitor with a good safety profile, is a newer option for CMV in SOT. Maribavir is approved for the treatment of refractory/resistant (R/R) CMV infection or disease in SOT and HCT recipients. In the SOLSTICE trial, a phase 3, open-label study of 352 HCT and SOT recipients with R/R CMV randomized to maribavir or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, cidofovir), maribavir was significantly more effective at CMV viremia clearance and symptom control along with fewer treatment discontinuations due to adverse effects compared to IAT [<xref rid="B31-viruses-16-01884" ref-type="bibr">31</xref>]. Small, single-center reports of maribavir use in SOT have been published but defining indications and understanding utilization are programmatic AVS responsibilities [<xref rid="B32-viruses-16-01884" ref-type="bibr">32</xref>]. Importantly, maribavir does not have activity against HSV or VZV, and prophylactic agents active against these viruses, e.g., (v)ACV, should be added if indicated.</p><p>Intravenous (IV) to oral (PO) conversion of antimicrobials is a main function of ASPs to avoid complications of intravenous therapy and decrease length of hospital stay [<xref rid="B33-viruses-16-01884" ref-type="bibr">33</xref>]. With strong evidence from the VICTOR trial establishing noninferiority of valganciclovir compared to IV ganciclovir for the treatment of CMV, IV to PO conversion of valganciclovir is an additional opportunity for AVS in SOT [<xref rid="B34-viruses-16-01884" ref-type="bibr">34</xref>]. Though case reports of antiviral therapeutic drug monitoring (TDM) have been described in SOT recipients, the lack of test availability and clinical guidance for therapeutic targets make this strategy an exciting area for potential future investigation [<xref rid="B35-viruses-16-01884" ref-type="bibr">35</xref>].</p></sec><sec id="sec2dot3-viruses-16-01884"><title>2.3. Laboratory Opportunities</title><p>Working with the local laboratory and transplant team to establish and protocolize diagnostic and screening guidance and virologic thresholds for CMV treatment may be a diagnostic stewardship opportunity for AVS programs [<xref rid="B15-viruses-16-01884" ref-type="bibr">15</xref>]. An outpatient, pharmacy-led intervention consisting of real-time CMV PCR surveillance and result notification coupled with drug therapy optimization recommendations resulted in more patients with CMV clearance and lower peak CMV viral loads [<xref rid="B36-viruses-16-01884" ref-type="bibr">36</xref>]. Additionally, appropriate CMV resistance testing (UL97 and UL54) should only be routinely sent if DNAemia persists or increases, or if CMV-related clinical symptoms do not resolve after at least 2 weeks of appropriately dosed (v)GCV therapy [<xref rid="B27-viruses-16-01884" ref-type="bibr">27</xref>]. Though the routine clinical role of CMV CMI testing may not be solidly established, opportunities to assess risk and personalize treatment for primary and secondary prophylaxis show promise as a future AVS tool [<xref rid="B37-viruses-16-01884" ref-type="bibr">37</xref>,<xref rid="B38-viruses-16-01884" ref-type="bibr">38</xref>]. Unfortunately, widespread protocolization and recommendations for testing are further challenged by the lack of commercial availability of certain CMV CMI assays (i.e., QuantiFERON-CMV) in the US. Antiviral stewardship opportunities and challenges in CMV in SOT are summarized in <xref rid="viruses-16-01884-t001" ref-type="table">Table 1</xref>. </p></sec></sec><sec id="sec3-viruses-16-01884"><title>3. Antiviral Stewardship for Cytomegalovirus After Hematopoietic Stem Cell Transplant</title><sec id="sec3dot1-viruses-16-01884"><title>3.1. CMV Prevention</title><p>Though CMV is a frequently encountered viral infection after allo-HCT associated with significant morbidity and mortality, to our knowledge there has been no comprehensively described AVS or CMV stewardship program described in the HCT population [<xref rid="B39-viruses-16-01884" ref-type="bibr">39</xref>]. The American Society for Transplantation and Cellular Therapy (ASTCT) guidelines recommend two complementary strategies for CMV prevention in CMV seropositive patients after allo-HCT in the early post-engraftment period: CMV monitoring for pre-emptive therapy (PET) and chemoprophylaxis with letermovir [<xref rid="B40-viruses-16-01884" ref-type="bibr">40</xref>]. In a landmark phase 3, double-blinded, randomized control trial of 495 CMV seropositive allo-HCT recipients by Marty et al., patients on letermovir prophylaxis through to week 14 had a significantly lower risk of clinically significant CMV infection compared to the placebo group at the week-24 follow-up [<xref rid="B22-viruses-16-01884" ref-type="bibr">22</xref>]. The impact of letermovir on the prevention of CMV infection and mortality was even more pronounced among patients at high risk for CMV reactivation [<xref rid="B22-viruses-16-01884" ref-type="bibr">22</xref>].</p><p>An additional factor to consider with the use of letermovir is the potential delay in the development of CMV-specific T-cell-mediated immunity (CMV-CMI) leading to late-stage CMV reactivation after discontinuation of prophylaxis. In the landmark trial by Marty et al., clinically significant CMV infection was reported in 10% of all patients and 20% of patients at high risk for CMV infection at the 24-week follow-up, 10 weeks after letermovir prophylaxis was discontinued [<xref rid="B22-viruses-16-01884" ref-type="bibr">22</xref>]. Similar findings were demonstrated in a phase 3, multicenter, double-blinded, randomized control trial of extended-duration letermovir prophylaxis in 220 CMV seropositive allo-HCT recipients at high risk of late CMV infection by Russo et al. [<xref rid="B25-viruses-16-01884" ref-type="bibr">25</xref>]. Extending letermovir prophylaxis from day 100 to day 200 was safe and effective in reducing the risk of clinically significant CMV infection; however, there was no significant difference in the incidence of clinically significant CMV reactivation by the 48-week follow-up, 20 weeks after letermovir prophylaxis was discontinued [<xref rid="B25-viruses-16-01884" ref-type="bibr">25</xref>]. The late-stage CMV reactivation in both trials was likely related to delays in the development of CMV-CMI. Zamora et al. demonstrated that patients on letermovir prophylaxis had decreased CMV-specific T-cell responses to multiple CMV antigens (immediate early-1 and phosphoprotein 65) compared to the PET group, possibly related to the suppression of CMV replication and decreased exposure to CMV antigens [<xref rid="B14-viruses-16-01884" ref-type="bibr">14</xref>].</p><p>A stewardship initiative to optimize letermovir use after allo-HCT involves targeting chemoprophylaxis for patients at high risk for CMV infection. High-risk patients are defined as CMV seropositive allo-HCT recipients having one or more of the following criteria: mismatched donor, haploidentical donor, use of umbilical cord blood as stem-cell source, and the use of ex vivo T-cell depleted grafts [<xref rid="B22-viruses-16-01884" ref-type="bibr">22</xref>,<xref rid="B25-viruses-16-01884" ref-type="bibr">25</xref>,<xref rid="B41-viruses-16-01884" ref-type="bibr">41</xref>]. A recent cost analysis comparing letermovir prophylaxis and PET through day +180 after allo-HCT found that letermovir was associated with significant reductions in CMV-related admissions and decreased the median total cost of care in high-risk CMV patients [<xref rid="B42-viruses-16-01884" ref-type="bibr">42</xref>]. Among patients at low risk for CMV reactivation not meeting any of the above criteria, CMV monitoring with PET may be a more beneficial preventative strategy to allow exposure to CMV antigens for the development of CMV-CMI.</p><p>Building on AVS strategies for CMV prevention in SOT recipients by Jorgenson et al., a proposed clinical algorithm involves routine monitoring of CMV-CMI in the early post-engraftment period to distinguish between allo-HCT recipients with ongoing risk of developing CMV infection and those who are protected [<xref rid="B3-viruses-16-01884" ref-type="bibr">3</xref>]. The REACT study demonstrated that allo-HCT patients with high CMV-CMI, as determined by a peptide-based enzyme linked immunospot (ELISPOT) CMV assay, were less likely to develop clinically significant CMV infection [<xref rid="B43-viruses-16-01884" ref-type="bibr">43</xref>]. Once CMV-CMI develops during routine monitoring after allo-HCT, CMV prevention strategies, including letermovir prophylaxis and CMV monitoring with PET, can likely be discontinued.</p></sec><sec id="sec3dot2-viruses-16-01884"><title>3.2. CMV Treatment</title><p>Similarly to SOT, the available therapies for CMV infection and disease in HCT are also limited by numerous adverse effects. The myelosuppressive effects of vGCV/GCV may require support with granulocyte colony-stimulating factor and are generally avoided during the pre-engraftment stage, and underdosing in HCT is a risk for development of drug-resistant CMV [<xref rid="B44-viruses-16-01884" ref-type="bibr">44</xref>]. Foscarnet is recommended for CMV treatment during the pre-engraftment stage, but toxicities are also seen in HCT patients [<xref rid="B45-viruses-16-01884" ref-type="bibr">45</xref>]. Cidofovir, reserved for third-line therapy, should be avoided when possible [<xref rid="B30-viruses-16-01884" ref-type="bibr">30</xref>].</p><p>Extrapolating from the results of the VICTOR trial, many subsequent studies have demonstrated that valganciclovir has equivalent clinical efficacy to ganciclovir for CMV pre-emptive therapy in HCT recipients [<xref rid="B34-viruses-16-01884" ref-type="bibr">34</xref>,<xref rid="B44-viruses-16-01884" ref-type="bibr">44</xref>,<xref rid="B46-viruses-16-01884" ref-type="bibr">46</xref>]. Even in the setting of mild intestinal graft-versus-host-disease (GVHD), valganciclovir achieves equivalent serum levels to ganciclovir [<xref rid="B47-viruses-16-01884" ref-type="bibr">47</xref>]. Therefore, intravenous GCV to oral vGCV conversion may also be a target for AVS activities in HCT recipients.</p><p>Based on the results of the SOLSTICE trial, maribavir is a promising agent for CMV PET after allo-HCT [<xref rid="B31-viruses-16-01884" ref-type="bibr">31</xref>]. Unfortunately, maribavir may not be as effective as vGCV for the treatment of first asymptomatic CMV infection after allo-SCT. In the AURORA trial, a multicenter, double-blind, phase 3 study of 547 HCT recipients with first asymptomatic CMV infection randomized to maribavir or valganciclovir, maribavir did not meet the primary endpoint of noninferiority for CMV viremia clearance (maribavir 69.9%, valganciclovir 77.4%) at week 8. However, patients treated with maribavir maintained CMV clearance without tissue-invasive disease at week 16 post-treatment follow-up. The maribavir group was less likely to develop neutropenia and require treatment discontinuation from adverse effects [<xref rid="B48-viruses-16-01884" ref-type="bibr">48</xref>]. Using hospital LOS data from the SOLSTICE trial and modeling CMV-related costs from the published literature, a recent US-based analysis led by maribavir&#x02019;s sponsor estimated that maribavir was likely associated with cost-savings when compared to IAT for R/R CMV [<xref rid="B49-viruses-16-01884" ref-type="bibr">49</xref>]. Additional studies are needed to determine the role of maribavir in the management of CMV infection in allo-HCT recipients.</p><p>CMV adoptive T-cell therapy is another promising treatment for the management of CMV infections, particularly in the setting of refractory and resistant CMV disease after HCT. Several nonrandomized clinical studies have demonstrated the safety and efficacy of donor-derived or third-party CMV-specific T-cells (CTLs) [<xref rid="B50-viruses-16-01884" ref-type="bibr">50</xref>]. Unfortunately, CTLs require a lengthy and expensive process of identifying HLA-matched CMV seropositive donors with subsequent isolation of CMV-specific T-cells for transfusion. Recent advances include the development of &#x0201c;off-the-shelf&#x0201d; third-party CTLs banks [<xref rid="B51-viruses-16-01884" ref-type="bibr">51</xref>,<xref rid="B52-viruses-16-01884" ref-type="bibr">52</xref>]. While CMV cellular therapies are currently limited by cost and availability, their widespread use could help avoid adverse drug effects and restore CMV immunity to prevent late-stage reactivation. However, the role of these therapies is currently uncertain, and experiences should be reported as further studies are needed. Antiviral stewardship challenges and opportunities in CMV after HCT are summarized in <xref rid="viruses-16-01884-t002" ref-type="table">Table 2</xref>.</p></sec></sec><sec id="sec4-viruses-16-01884"><title>4. Antiviral Stewardship for Respiratory Syncytial Virus</title><p>RSV is a frequently encountered community-acquired respiratory virus in transplant recipients associated with significant morbidity and mortality in immunocompromised hosts [<xref rid="B53-viruses-16-01884" ref-type="bibr">53</xref>,<xref rid="B54-viruses-16-01884" ref-type="bibr">54</xref>]. Among allo-HCT and lung transplant recipients, RSV upper respiratory infections (URIs) are more likely to progress to lower respiratory tract disease (LRD) with resulting respiratory failure and death [<xref rid="B55-viruses-16-01884" ref-type="bibr">55</xref>]. Lung transplant recipients can also suffer from chronic sequelae after severe RSV infections as immune dysregulation can lead to chronic lung allograft dysfunction [<xref rid="B56-viruses-16-01884" ref-type="bibr">56</xref>]. Ribavirin is a nucleoside analogue with in vitro activity against RSV. As there are no large prospective randomized double-blinded clinical trials on the safety and efficacy of ribavirin, there is no consensus on the optimal treatment of RSV in HCT and SOT recipients [<xref rid="B53-viruses-16-01884" ref-type="bibr">53</xref>,<xref rid="B54-viruses-16-01884" ref-type="bibr">54</xref>]. Based on data from observational studies, current clinical guidelines recommend considering the use of ribavirin in severely immunocompromised patients where treatment may reduce progression to LRD and death [<xref rid="B53-viruses-16-01884" ref-type="bibr">53</xref>,<xref rid="B54-viruses-16-01884" ref-type="bibr">54</xref>].</p><p>An important AVS initiative is reserving the use of ribavirin for patients who would receive the most clinical benefit from treatment as the drug is associated with hematologic toxicities including anemia, hemolytic anemia, neutropenia, and lymphopenia [<xref rid="B57-viruses-16-01884" ref-type="bibr">57</xref>]. Among allo-HCT recipients, patients who are severely immunocompromised when presenting in the earliest stages of RSV URI may benefit the most from ribavirin therapy. Shah et al. developed the Immunodeficiency Scoring Index (ISI)-RSV that stratified allo-HCT recipients into three risk groups (low, moderate, and high) based on six immunodeficiency markers immediately available on routine bloodwork: age <inline-formula><mml:math id="mm1" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> 40 years, absolute neutrophil count (ANC) &#x0003c; 500/&#x003bc;L, absolute lymphocyte count (ALC) &#x0003c; 200/&#x003bc;L, myeloablative conditioning regimen, acute or chronic GVHD, corticosteroids, and recent or pre-engraftment allo-HCT. The study found that in a cohort of 237 allo-HCT recipients, those with high risk based on the ISI-RSV benefited the most from ribavirin when administered during the URI stage, and they had the highest risk of progression to LRD and death when ribavirin was not initiated [<xref rid="B58-viruses-16-01884" ref-type="bibr">58</xref>].</p><p>An AVS initiative to optimize ribavirin use identifies allo-HCT recipients early in the RSV disease course and reserves ribavirin for patients determined to be at high risk for severe disease. For a timely diagnosis of RSV, all allo-HCT recipients presenting in the outpatient or inpatient setting with URI symptoms would immediately be tested using a multiple polymerase chain reaction (PCR) respiratory viral panel. The decision to treat would be based on the patient&#x02019;s risk for progression to LRD using the ISI-RSV. Additional risk factors for progression from URI to LRD to consider when deciding to initiate ribavirin include history of smoking, total body irradiation &#x0003e; 1200 cGy, use of a mismatched or unrelated donor, multiple transplantations procedures, prior exposure to antibiotics, and serum glucose &#x0003e; 200 mg/dL [<xref rid="B53-viruses-16-01884" ref-type="bibr">53</xref>]. Transplant centers can consider incorporating these risk factors into treatment algorithms to assist with clinical decision making.</p><p>Another AVS opportunity involves replacing aerosolized ribavirin with the oral formulation for the treatment of RSV in severely immunocompromised hosts. The initial studies demonstrating a potential clinical benefit of ribavirin used the aerosolized formulation for the treatment of RSV [<xref rid="B59-viruses-16-01884" ref-type="bibr">59</xref>,<xref rid="B60-viruses-16-01884" ref-type="bibr">60</xref>,<xref rid="B61-viruses-16-01884" ref-type="bibr">61</xref>]. However, there are many drawbacks to aerosolized ribavirin, including the risk of bronchospasm, pulmonary edema, dyspnea, and impaired ventilation and oxygenation in the patient. An additional limitation to ribavirin includes its potential teratogenicity to healthcare providers exposed to the drug. Administration of aerosolized ribavirin requires a scavenging tent, a process that is challenging for the respiratory therapist and uncomfortable for patients who may already be experiencing respiratory distress [<xref rid="B62-viruses-16-01884" ref-type="bibr">62</xref>]. The decision to initiate treatment with aerosolized ribavirin is challenging as clinicians must weigh the potential risks with unknown clinical benefit given the minimal evidence supporting its use.</p><p>Subsequent research has demonstrated that oral and aerosolized ribavirin formulations have similar efficacy in the treatment of RSV for both allo-HCT and lung transplant recipients [<xref rid="B63-viruses-16-01884" ref-type="bibr">63</xref>,<xref rid="B64-viruses-16-01884" ref-type="bibr">64</xref>]. A retrospective cohort study of 124 allo-HCT recipients with RSV infection found that the rate of progression to LRD and 30-day mortality were similar among those treated with oral and nebulized ribavirin [<xref rid="B63-viruses-16-01884" ref-type="bibr">63</xref>]. In a retrospective study of 52 lung transplant recipients with symptomatic RSV infection, oral ribavirin was found to be an effective and well-tolerated alternative to inhaled ribavirin with associated cost savings and reduced length of hospital stay [<xref rid="B64-viruses-16-01884" ref-type="bibr">64</xref>]. Restricting adult hospital formularies to oral ribavirin may decrease healthcare costs and prevent adverse effects in patients and healthcare workers.</p><p>The US Food and Drug Administration has approved multiple safe and effective vaccines for the prevention of RSV LRD in adults <inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> 60 years: adjuvant monovalent vaccine Arexvy, nonadjuvanted bivalent vaccine Abrysvo, and the mRNA vaccine mResvia [<xref rid="B65-viruses-16-01884" ref-type="bibr">65</xref>]. Widespread immunization of immunocompromised patients at high risk for LRD is the most impactful stewardship intervention to decrease the incidence of symptomatic RSV, prevent hospitalizations, and obviate the need for ribavirin. As the vaccines clinical trials did not include immunocompromised hosts, there are no clinical guidelines on their use among SOT and HCT recipients [<xref rid="B66-viruses-16-01884" ref-type="bibr">66</xref>,<xref rid="B67-viruses-16-01884" ref-type="bibr">67</xref>,<xref rid="B68-viruses-16-01884" ref-type="bibr">68</xref>]. The immunogenicity of RSV vaccine among immunocompromised hosts is an active area of research that will guide future recommendations on the optimal age of vaccine initiation and the frequency of boosters. Based on the available information, an AVS strategy to increase RSV vaccination rates involves the routine recommendation of RSV vaccines during pretransplant counseling visits to ensure that vaccines are administered prior to the onset of immunosuppression. For pre- and post-transplant patients <inline-formula><mml:math id="mm3" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02264;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> 60 years, shared clinical decision making between the clinician and the patient is encouraged to discuss the potential benefits while weighing the possible out-of-pocket cost for the vaccine. Considerations for AVS for RSV after transplantation are summarized in <xref rid="viruses-16-01884-t003" ref-type="table">Table 3</xref>.</p><sec id="sec4dot1-viruses-16-01884"><title>4.1. Antiviral Stewardship for SARS-CoV-2</title><p>Immunosuppression has been associated with an increased risk of COVID-19-related hospitalizations in SOT recipients [<xref rid="B69-viruses-16-01884" ref-type="bibr">69</xref>]. While a majority of HCT and SOT patients appear to have lower disease severity from infections with current variants, certain groups, such as lung transplant recipients, may still experience severe COVID-19 [<xref rid="B70-viruses-16-01884" ref-type="bibr">70</xref>,<xref rid="B71-viruses-16-01884" ref-type="bibr">71</xref>]. Unfortunately, resistance development on therapy has been described in immunocompromised patients [<xref rid="B72-viruses-16-01884" ref-type="bibr">72</xref>].</p><p>Transplant recipients were largely excluded from early-pandemic, antiviral trials, and large, robust studies in transplant populations are lacking. There have been prospective and retrospective studies evaluating antiviral interventions (remdesivir, nirmatrelvir/ritonavir, molnupiravir) in transplant recipients with COVID-19 [<xref rid="B73-viruses-16-01884" ref-type="bibr">73</xref>,<xref rid="B74-viruses-16-01884" ref-type="bibr">74</xref>,<xref rid="B75-viruses-16-01884" ref-type="bibr">75</xref>]. The Infectious Diseases Society of America (IDSA) treatment guidelines do not give specific antiviral treatment recommendations for transplant recipients, though currently available guidance from transplant experts is similar [<xref rid="B76-viruses-16-01884" ref-type="bibr">76</xref>,<xref rid="B77-viruses-16-01884" ref-type="bibr">77</xref>,<xref rid="B78-viruses-16-01884" ref-type="bibr">78</xref>]. For patients with mild to moderate COVID-19, guideline-recommended options are remdesivir (3 days), nirmatrelvir&#x02013;ritonavir, or molnupiravir, or neutralizing monoclonal antibodies and 5 days of remdesivir if patients have severe COVID-19 and are on supplemental oxygen. Though nirmatrelvir-ritonavir has been safely used in SOT and HCT recipients, ritonavir&#x02019;s strong inhibition of cytochrome P450 3A4 leads to a substantial interaction with calcineurin inhibitors (CNIs), which may lead to severe toxicities [<xref rid="B75-viruses-16-01884" ref-type="bibr">75</xref>].</p><p>The changing variant landscape and immunity conferred from prior infection and SARS-CoV-2 vaccination further challenges understanding of the most ideal patient, time, and setting of antiviral interventions. AVS initiatives for SARS-CoV-2 may focus on institutional protocols supporting clinicians to understand an individual SOT/HCT recipient&#x02019;s risk of severe disease and subsequent need for antivirals in low-risk, vaccinated patients with mild symptoms. Additionally, ensuring appropriate durations of remdesivir based on disease severity (3 days mild&#x02013;moderate; 5 days for severe) may be another opportunity for AVS monitoring. Working with transplant pharmacy teams to support management and patient education regarding nirmatrelvir&#x02013;ritonavir CNI interactions may also be beneficial. To avoid unnecessary antivirals, AVS for SARS-CoV-2 should include diagnostic stewardship, avoiding screening of asymptomatic patients in most circumstances in the pre- and post-transplant setting. The use of immunomodulatory agents for patients with severe COVID-19 may also be an opportunity for AVS support, though this is beyond the scope of this review. Considerations for AVS for SARS-CoV-2 after transplantation are summarized in <xref rid="viruses-16-01884-t004" ref-type="table">Table 4</xref>.</p></sec><sec id="sec4dot2-viruses-16-01884"><title>4.2. Antiviral Stewardship for HSV/VZV</title><p>After SOT, most recipients receive vGCV prophylaxis, which generally provides protection against HSV and VZV reactivations. In some situations, (v)ACV may be given instead of vGCV (toxicity, cost, CMV D-/R-) for a recommended duration of at least 1 month or after episodes of rejection [<xref rid="B79-viruses-16-01884" ref-type="bibr">79</xref>]. After HCT, HSV risk is highest in the early post-transplant period. ACV prophylaxis decreases HSV and VZV reactivation [<xref rid="B80-viruses-16-01884" ref-type="bibr">80</xref>]. The National Comprehensive Cancer Network (NCCN) recommends HSV prophylaxis for a minimum of 2 months after alemtuzumab and until CD4 &#x02265; 200 cells/mcL and VZV prophylaxis for at least 1 year after allogeneic HCT [<xref rid="B81-viruses-16-01884" ref-type="bibr">81</xref>].</p><p>Optimizing institutional protocols for prophylaxis and treatment and attempting to monitor prescription indications for (v)ACV is an additional opportunity for AVS. Further, in coordination with transplant pharmacy clinicians, AVS should work to ensure that patients who are prescribed letermovir for CMV prophylaxis (after SOT or HCT) and/or maribavir for refractory/resistant CMV therapy are also on an HSV/VZV-active agent such as (v)ACV if they meet the criteria to receive HSV/VZV prophylaxis.</p><p>Empiric ACV for patients with presumed HSV or VZV encephalitis is commonly encountered in clinical practice. Studies including transplant and immunocompromised patients have reported decreases in ACV utilization after implementation of meningitis encephalitis panels, which may support AVS [<xref rid="B82-viruses-16-01884" ref-type="bibr">82</xref>,<xref rid="B83-viruses-16-01884" ref-type="bibr">83</xref>]. However, it is important to keep in mind that false-negative HSV PCR results have been reported from meningitis encephalitis panels, and HSV 1/2-specific PCR testing should be considered if concern for infection remains [<xref rid="B84-viruses-16-01884" ref-type="bibr">84</xref>].</p></sec><sec id="sec4dot3-viruses-16-01884"><title>4.3. Antiviral Stewardship for EBV</title><p>In patients who have undergone SOT or HCT, EBV reactivation is common and can be associated with a variety of clinical syndromes. However, EBV-associated post-transplant lymphoproliferative disorder is the most concerning and challenging. Though monitoring EBV DNAemia is common after SOT and HCT, relevant thresholds dictating interventions and predicting PTLD across different organs transplanted, as well as variability across labs, further challenges EBV management in transplantation. EBV DNAemia monitoring for allo-HCT recipients is recommended to begin within the first month post-transplant and continue weekly for at least 4 months and longer if patients are suspected to have poor T-cell reconstitution [<xref rid="B85-viruses-16-01884" ref-type="bibr">85</xref>]. In EBV-negative SOT recipients of EBV seropositive donors, EBV DNA monitoring is recommended weekly to biweekly in the first year after transplant [<xref rid="B86-viruses-16-01884" ref-type="bibr">86</xref>]. In patients who develop EBV DNAemia (center-defined threshold), weekly rituximab is the first-line agent for preemptive therapy and is given weekly for 1&#x02013;4 doses or until EBV DNAemia negativity and should be combined with immunosuppression reduction when possible [<xref rid="B85-viruses-16-01884" ref-type="bibr">85</xref>]. In SOT recipients with EBV DNAemia, a reduction in immunosuppression is the first-line recommended management strategy, as data using rituximab therapy are limited [<xref rid="B86-viruses-16-01884" ref-type="bibr">86</xref>]. EBV DNA monitoring after HCT or mismatched SOT may be an opportunity for diagnostic stewardship. Optimization of rituximab prescription may also be supported by AVS programs targeting center-specific guideline adherence in order to decrease practice variability.</p><p>While ACV and GCV have in vitro activity against lytic forms of EBV, and the lytic cycle is associated with the progression of EBV tumors, latent EBV-driven lymphoproliferation predominates in PTLD lesions [<xref rid="B87-viruses-16-01884" ref-type="bibr">87</xref>]. However, ACV and GCV have no impact on latent EBV infection. Though some single- and multicenter retrospective studies suggest that antiviral prophylaxis reduces PTLD incidence, larger, more methodologically robust studies demonstrate otherwise [<xref rid="B86-viruses-16-01884" ref-type="bibr">86</xref>]. Therefore, the use of antivirals, (v)ACV and (v)GCV, for prophylaxis or preemptive therapy to prevent EBV-positive PTLD is not recommended after SOT or HCT [<xref rid="B85-viruses-16-01884" ref-type="bibr">85</xref>,<xref rid="B86-viruses-16-01884" ref-type="bibr">86</xref>]. Similarly, there is insufficient evidence to support the routine use of antiviral therapy for the treatment of EBV-positive PTLD after SOT or HCT [<xref rid="B85-viruses-16-01884" ref-type="bibr">85</xref>,<xref rid="B86-viruses-16-01884" ref-type="bibr">86</xref>]. Considering that the totality of data does not support antivirals for EBV, and national and international guidelines recommend that antivirals should not be used, antiviral utilization for the prevention or treatment of EBV may be an opportunity for AVS through the creation of institutional guidance and monitoring drug utilization for this indication. If available, cellular therapy, such as EBV-specific CTLs, is recommended to prevent and treat PTLD after HCT but not after SOT, given limited data [<xref rid="B85-viruses-16-01884" ref-type="bibr">85</xref>,<xref rid="B86-viruses-16-01884" ref-type="bibr">86</xref>]. The role of CTLs in AVS has not yet been determined and needs further study. Emerging diagnostics, such as those testing for the Z EBV replication activator (ZEBRA) protein, identifying lytic virus, have been studied in transplant recipients, and newer strategies to inhibit EBV lytic replication are being explored [<xref rid="B88-viruses-16-01884" ref-type="bibr">88</xref>,<xref rid="B89-viruses-16-01884" ref-type="bibr">89</xref>]. The future role for these diagnostic and therapeutic interventions within AVS programs remains to be determined. Considerations for AVS for EBV after transplantation are summarized in <xref rid="viruses-16-01884-t005" ref-type="table">Table 5</xref>.</p></sec><sec id="sec4dot4-viruses-16-01884"><title>4.4. Antiviral Stewardship for BK Polyomavirus in Transplantation</title><p>Lowering immunosuppression is the primary recommended management strategy for BKPyV DNAemia or related disease. Though cidofovir has in vitro activity against BKPyV, there are no prospective, well-controlled trials demonstrating clinical efficacy, and, ideally, it should be avoided in kidney transplant recipients where BKpyV is most commonly managed [<xref rid="B90-viruses-16-01884" ref-type="bibr">90</xref>]. Recently updated international guidelines recommend against the use of cidofovir for BKPyV DNAemia or nephropathy in kidney transplant recipients [<xref rid="B91-viruses-16-01884" ref-type="bibr">91</xref>]. Additionally, though past clinical reports of fluoroquinolones&#x02019; impacts on BK-related disease have been mixed, a more recent systematic review and two prospective RCTs found that quinolones did not prevent BKPyV DNAemia or disease and, in one study, were associated with increased rates of fluroquinolone-resistant infections [<xref rid="B92-viruses-16-01884" ref-type="bibr">92</xref>,<xref rid="B93-viruses-16-01884" ref-type="bibr">93</xref>,<xref rid="B94-viruses-16-01884" ref-type="bibr">94</xref>]. Consequently, recent guidelines recommend against the use of fluroquinolones to prevent or treat BKPyV DNAemia or nephropathy after kidney transplantation [<xref rid="B91-viruses-16-01884" ref-type="bibr">91</xref>]. Similarly, systemic cidofovir has been evaluated for the treatment of BKPyV-associated hemorrhagic cystitis in patients after HCT in small, observational studies with mixed results and should not be routinely used [<xref rid="B5-viruses-16-01884" ref-type="bibr">5</xref>,<xref rid="B95-viruses-16-01884" ref-type="bibr">95</xref>].</p></sec></sec><sec id="sec5-viruses-16-01884"><title>5. Potential Antiviral Stewardship Program Metrics</title><p>Evaluating and reporting metrics are recommended for ASPs in the general population, though transplant-specific metrics, particularly ideal AVS measures, are not as well understood [<xref rid="B33-viruses-16-01884" ref-type="bibr">33</xref>]. Results from a 2015 survey by Seo et al. found that 23% of transplant programs that included SOT/HCT in ASPs did not track outcome metrics in these patient groups [<xref rid="B96-viruses-16-01884" ref-type="bibr">96</xref>]. Metrics used in the comprehensive CMV stewardship program described by Jorgenson et al. included antiviral utilization, rates of GCV-resistant CMV, and hospital admission and duration for IV foscarnet [<xref rid="B3-viruses-16-01884" ref-type="bibr">3</xref>]. AVS process metrics may focus on institutional guideline adherence, diagnostic optimization, and appropriateness of antivirals (e.g., inhaled or PO ribavirin, letermovir, and maribavir). Outcome and balancing metrics such as CMV DNAemia and disease recurrence, related hospitalizations, adverse drug events, and resistance are more resource-intensive and may be more challenging to monitor. Examples of antiviral stewardship program metrics are summarized in <xref rid="viruses-16-01884-t006" ref-type="table">Table 6</xref>.</p></sec><sec sec-type="conclusions" id="sec6-viruses-16-01884"><title>6. Conclusions</title><p>There are significant opportunities for AVS in transplant recipients to optimize patient outcomes. Though AVS can be easily integrated with institutional ASPs, further research on program structure, optimal interventions, and valuable metrics is needed.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: S.B., S.T. and J.H.; original draft preparation: S.B., S.T. and J.H.; review and editing, J.H.; supervision, J.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>S.B.&#x02014;none; S.T.&#x02014;none; J.H. grant/research: Pfizer, Janssen, Rebiotix, Scynexis, AstraZeneca, ARLG, NIH/NIAID; Advisory Board: Pfizer, AstraZeneca, Innoviva; Honoraria: The Antibiotic Resistance Leadership Group (ARLG).</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01884"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>So</surname><given-names>M.</given-names></name>
<name><surname>Hand</surname><given-names>J.</given-names></name>
<name><surname>Forrest</surname><given-names>G.</given-names></name>
<name><surname>Pouch</surname><given-names>S.M.</given-names></name>
<name><surname>Te</surname><given-names>H.</given-names></name>
<name><surname>Ardura</surname><given-names>M.I.</given-names></name>
<name><surname>Bartash</surname><given-names>R.M.</given-names></name>
<name><surname>Dadhania</surname><given-names>D.M.</given-names></name>
<name><surname>Edelman</surname><given-names>J.</given-names></name>
<name><surname>Ince</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>White paper on antimicrobial stewardship in solid organ transplant recipients</article-title><source>Am. J. Transplant.</source><year>2022</year><volume>22</volume><fpage>96</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1111/ajt.16743</pub-id><pub-id pub-id-type="pmid">34212491</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01884"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gyssens</surname><given-names>I.C.</given-names></name>
<name><surname>Kern</surname><given-names>W.V.</given-names></name>
<name><surname>Livermore</surname><given-names>D.M.</given-names></name>
</person-group><article-title>The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients</article-title><source>Haematologica</source><year>2013</year><volume>98</volume><fpage>1821</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.3324/haematol.2013.091769</pub-id><pub-id pub-id-type="pmid">24323982</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01884"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jorgenson</surname><given-names>M.R.</given-names></name>
<name><surname>Descourouez</surname><given-names>J.L.</given-names></name>
<name><surname>Kleiboeker</surname><given-names>H.</given-names></name>
<name><surname>Goldrosen</surname><given-names>K.</given-names></name>
<name><surname>Schulz</surname><given-names>L.</given-names></name>
<name><surname>Rice</surname><given-names>J.P.</given-names></name>
<name><surname>Odorico</surname><given-names>J.S.</given-names></name>
<name><surname>Mandelbrot</surname><given-names>D.A.</given-names></name>
<name><surname>Smith</surname><given-names>J.A.</given-names></name>
<name><surname>Saddler</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard</article-title><source>Transpl. Infect. Dis.</source><year>2022</year><volume>24</volume><fpage>e13864</fpage><pub-id pub-id-type="doi">10.1111/tid.13864</pub-id><pub-id pub-id-type="pmid">35603982</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01884"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jorgenson</surname><given-names>M.R.</given-names></name>
<name><surname>Descourouez</surname><given-names>J.L.</given-names></name>
<name><surname>Schulz</surname><given-names>L.T.</given-names></name>
<name><surname>Goldrosen</surname><given-names>K.A.</given-names></name>
<name><surname>Rice</surname><given-names>J.P.</given-names></name>
<name><surname>Redfield</surname><given-names>R.R.</given-names></name>
<name><surname>Saddler</surname><given-names>C.M.</given-names></name>
<name><surname>Smith</surname><given-names>J.A.</given-names></name>
<name><surname>Mandelbrot</surname><given-names>D.A.</given-names></name>
</person-group><article-title>The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2020</year><volume>41</volume><fpage>1068</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1017/ice.2020.203</pub-id><pub-id pub-id-type="pmid">32456718</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01884"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dadwal</surname><given-names>S.S.</given-names></name>
<name><surname>Papanicolaou</surname><given-names>G.A.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
</person-group><article-title>How I prevent viral reactivation in high-risk patients</article-title><source>Blood</source><year>2023</year><volume>141</volume><fpage>2062</fpage><lpage>2074</lpage><pub-id pub-id-type="doi">10.1182/blood.2021014676</pub-id><pub-id pub-id-type="pmid">36493341</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01884"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neofytos</surname><given-names>D.</given-names></name>
<name><surname>Ojha</surname><given-names>A.</given-names></name>
<name><surname>Mookerjee</surname><given-names>B.</given-names></name>
<name><surname>Wagner</surname><given-names>J.</given-names></name>
<name><surname>Filicko</surname><given-names>J.</given-names></name>
<name><surname>Ferber</surname><given-names>A.</given-names></name>
<name><surname>Dessain</surname><given-names>S.</given-names></name>
<name><surname>Grosso</surname><given-names>D.</given-names></name>
<name><surname>Brunner</surname><given-names>J.</given-names></name>
<name><surname>Flomenberg</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Treatment of adenovirus disease in stem cell transplant recipients with cidofovir</article-title><source>Biol. Blood Marrow Transplant.</source><year>2007</year><volume>13</volume><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2006.08.040</pub-id><pub-id pub-id-type="pmid">17222755</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01884"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riva</surname><given-names>G.</given-names></name>
<name><surname>Luppi</surname><given-names>M.</given-names></name>
<name><surname>Barozzi</surname><given-names>P.</given-names></name>
<name><surname>Forghieri</surname><given-names>F.</given-names></name>
<name><surname>Potenza</surname><given-names>L.</given-names></name>
</person-group><article-title>How I treat HHV8/KSHV-related diseases in posttransplant patients</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>4150</fpage><lpage>4159</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-04-421412</pub-id><pub-id pub-id-type="pmid">22968461</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01884"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toomey</surname><given-names>D.</given-names></name>
<name><surname>Phan</surname><given-names>T.L.</given-names></name>
<name><surname>Nguyen</surname><given-names>V.</given-names></name>
<name><surname>Phan</surname><given-names>T.T.</given-names></name>
<name><surname>Ogata</surname><given-names>M.</given-names></name>
</person-group><article-title>Retrospective case analysis of antiviral therapies for HHV-6 encephalitis after hematopoietic stem cell transplantation</article-title><source>Transpl. Infect. Dis.</source><year>2021</year><volume>23</volume><fpage>e13443</fpage><pub-id pub-id-type="doi">10.1111/tid.13443</pub-id><pub-id pub-id-type="pmid">32786154</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01884"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waghmare</surname><given-names>A.</given-names></name>
<name><surname>Campbell</surname><given-names>A.P.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Seo</surname><given-names>S.</given-names></name>
<name><surname>Kuypers</surname><given-names>J.</given-names></name>
<name><surname>Leisenring</surname><given-names>W.</given-names></name>
<name><surname>Jerome</surname><given-names>K.R.</given-names></name>
<name><surname>Englund</surname><given-names>J.A.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
</person-group><article-title>Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: Viral RNA detection in blood, antiviral treatment, and clinical outcomes</article-title><source>Clin. Infect. Dis.</source><year>2013</year><volume>57</volume><fpage>1731</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.1093/cid/cit639</pub-id><pub-id pub-id-type="pmid">24065324</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01884"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>C.E.</given-names></name>
<name><surname>Knudsen</surname><given-names>J.L.</given-names></name>
<name><surname>Lease</surname><given-names>E.D.</given-names></name>
<name><surname>Jerome</surname><given-names>K.R.</given-names></name>
<name><surname>Rakita</surname><given-names>R.M.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
<name><surname>Limaye</surname><given-names>A.P.</given-names></name>
</person-group><article-title>Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>65</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1093/cid/cix259</pub-id><pub-id pub-id-type="pmid">28369203</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01884"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Acquier</surname><given-names>M.</given-names></name>
<name><surname>Taton</surname><given-names>B.</given-names></name>
<name><surname>Alain</surname><given-names>S.</given-names></name>
<name><surname>Garrigue</surname><given-names>I.</given-names></name>
<name><surname>Mary</surname><given-names>J.</given-names></name>
<name><surname>Pfirmann</surname><given-names>P.</given-names></name>
<name><surname>Visentin</surname><given-names>J.</given-names></name>
<name><surname>Hantz</surname><given-names>S.</given-names></name>
<name><surname>Merville</surname><given-names>P.</given-names></name>
<name><surname>Kaminski</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Cytomegalovirus DNAemia Requiring (Val)Ganciclovir Treatment for More Than 8 Weeks Is a Key Factor in the Development of Antiviral Drug Resistance</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><volume>10</volume><fpage>ofad018</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofad018</pub-id><pub-id pub-id-type="pmid">36817745</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01884"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chou</surname><given-names>S.</given-names></name>
<name><surname>Alain</surname><given-names>S.</given-names></name>
<name><surname>Cervera</surname><given-names>C.</given-names></name>
<name><surname>Chemaly</surname><given-names>R.F.</given-names></name>
<name><surname>Kotton</surname><given-names>C.N.</given-names></name>
<name><surname>Lundgren</surname><given-names>J.</given-names></name>
<name><surname>Papanicolaou</surname><given-names>G.A.</given-names></name>
<name><surname>Pereira</surname><given-names>M.R.</given-names></name>
<name><surname>Wu</surname><given-names>J.J.</given-names></name>
<name><surname>Murray</surname><given-names>R.A.</given-names></name>
<etal/>
</person-group><article-title>Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients</article-title><source>J. Infect. Dis.</source><year>2024</year><volume>229</volume><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiad293</pub-id><pub-id pub-id-type="pmid">37506264</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01884"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hofmann</surname><given-names>E.</given-names></name>
<name><surname>Sidler</surname><given-names>D.</given-names></name>
<name><surname>Dahdal</surname><given-names>S.</given-names></name>
<name><surname>Bittel</surname><given-names>P.</given-names></name>
<name><surname>Suter-Riniker</surname><given-names>F.</given-names></name>
<name><surname>Manuel</surname><given-names>O.</given-names></name>
<name><surname>Walti</surname><given-names>L.N.</given-names></name>
<name><surname>Hirzel</surname><given-names>C.</given-names></name>
</person-group><article-title>Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature</article-title><source>Transpl. Infect. Dis.</source><year>2021</year><volume>23</volume><fpage>e13515</fpage><pub-id pub-id-type="doi">10.1111/tid.13515</pub-id><pub-id pub-id-type="pmid">33210830</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01884"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zamora</surname><given-names>D.</given-names></name>
<name><surname>Duke</surname><given-names>E.R.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Edmison</surname><given-names>B.C.</given-names></name>
<name><surname>Akoto</surname><given-names>B.</given-names></name>
<name><surname>Kiener</surname><given-names>R.</given-names></name>
<name><surname>Stevens-Ayers</surname><given-names>T.</given-names></name>
<name><surname>Wagner</surname><given-names>R.</given-names></name>
<name><surname>Mielcarek</surname><given-names>M.</given-names></name>
<name><surname>Leisenring</surname><given-names>W.M.</given-names></name>
<etal/>
</person-group><article-title>Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation</article-title><source>Blood</source><year>2021</year><volume>138</volume><fpage>34</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1182/blood.2020009396</pub-id><pub-id pub-id-type="pmid">33657225</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01884"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kotton</surname><given-names>C.N.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<name><surname>Caliendo</surname><given-names>A.M.</given-names></name>
<name><surname>Huprikar</surname><given-names>S.</given-names></name>
<name><surname>Chou</surname><given-names>S.</given-names></name>
<name><surname>Danziger-Isakov</surname><given-names>L.</given-names></name>
<name><surname>Humar</surname><given-names>A.</given-names></name>
<collab>The Transplantation Society International CMV Consensus Group</collab>
</person-group><article-title>The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation</article-title><source>Transplantation</source><year>2018</year><volume>102</volume><fpage>900</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000002191</pub-id><pub-id pub-id-type="pmid">29596116</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01884"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Winston</surname><given-names>D.J.</given-names></name>
<name><surname>Razonable</surname><given-names>R.R.</given-names></name>
<name><surname>Lyon</surname><given-names>G.M.</given-names></name>
<name><surname>Silveira</surname><given-names>F.P.</given-names></name>
<name><surname>Wagener</surname><given-names>M.M.</given-names></name>
<name><surname>Stevens-Ayers</surname><given-names>T.</given-names></name>
<name><surname>Edmison</surname><given-names>B.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
<name><surname>Limaye</surname><given-names>A.P.</given-names></name>
</person-group><article-title>Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients with Seropositive Donors: A Randomized Clinical Trial</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1378</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.3138</pub-id><pub-id pub-id-type="pmid">32286644</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01884"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Limaye</surname><given-names>A.P.</given-names></name>
<name><surname>Green</surname><given-names>M.L.</given-names></name>
<name><surname>Edmison</surname><given-names>B.C.</given-names></name>
<name><surname>Stevens-Ayers</surname><given-names>T.</given-names></name>
<name><surname>Chatterton-Kirchmeier</surname><given-names>S.</given-names></name>
<name><surname>Geballe</surname><given-names>A.P.</given-names></name>
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
</person-group><article-title>Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>220</volume><fpage>752</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz181</pub-id><pub-id pub-id-type="pmid">31112280</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01884"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>L.</given-names></name>
<name><surname>Dasgupta</surname><given-names>S.</given-names></name>
<name><surname>Murray-Krezan</surname><given-names>C.</given-names></name>
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Rakita</surname><given-names>R.M.</given-names></name>
<name><surname>Fisher</surname><given-names>C.E.</given-names></name>
<name><surname>Limaye</surname><given-names>A.P.</given-names></name>
</person-group><article-title>Association of Cytomegalovirus (CMV) DNAemia with Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>78</volume><fpage>719</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1093/cid/ciad643</pub-id><pub-id pub-id-type="pmid">37862162</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01884"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Limaye</surname><given-names>A.P.</given-names></name>
<name><surname>Budde</surname><given-names>K.</given-names></name>
<name><surname>Humar</surname><given-names>A.</given-names></name>
<name><surname>Vincenti</surname><given-names>F.</given-names></name>
<name><surname>Kuypers</surname><given-names>D.R.J.</given-names></name>
<name><surname>Carroll</surname><given-names>R.P.</given-names></name>
<name><surname>Stauffer</surname><given-names>N.</given-names></name>
<name><surname>Murata</surname><given-names>Y.</given-names></name>
<name><surname>Strizki</surname><given-names>J.M.</given-names></name>
<name><surname>Teal</surname><given-names>V.L.</given-names></name>
<etal/>
</person-group><article-title>Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial</article-title><source>JAMA</source><year>2023</year><volume>330</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.9106</pub-id><pub-id pub-id-type="pmid">37279999</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01884"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kleiboeker</surname><given-names>H.L.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Borkowski</surname><given-names>N.</given-names></name>
<name><surname>Miner</surname><given-names>B.</given-names></name>
<name><surname>Prom</surname><given-names>A.</given-names></name>
<name><surname>Paplaczyk</surname><given-names>K.</given-names></name>
<name><surname>Wright</surname><given-names>J.</given-names></name>
<name><surname>Subramani</surname><given-names>M.V.</given-names></name>
<name><surname>Arunachalam</surname><given-names>A.</given-names></name>
<name><surname>Betensley</surname><given-names>A.D.</given-names></name>
<etal/>
</person-group><article-title>Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients</article-title><source>Transpl. Infect. Dis.</source><year>2024</year><volume>26</volume><fpage>e14337</fpage><pub-id pub-id-type="doi">10.1111/tid.14337</pub-id><pub-id pub-id-type="pmid">38980979</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01884"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saltiel</surname><given-names>G.</given-names></name>
<name><surname>Faure</surname><given-names>E.</given-names></name>
<name><surname>Assaf</surname><given-names>A.</given-names></name>
<name><surname>Chopin</surname><given-names>M.C.</given-names></name>
<name><surname>Moreau</surname><given-names>F.</given-names></name>
<name><surname>Faure</surname><given-names>K.</given-names></name>
<name><surname>Goeminne</surname><given-names>C.</given-names></name>
<name><surname>Vuotto</surname><given-names>F.</given-names></name>
</person-group><article-title>Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients</article-title><source>Clin. Transplant.</source><year>2024</year><volume>38</volume><fpage>e15327</fpage><pub-id pub-id-type="doi">10.1111/ctr.15327</pub-id><pub-id pub-id-type="pmid">38686437</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01884"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marty</surname><given-names>F.M.</given-names></name>
<name><surname>Ljungman</surname><given-names>P.</given-names></name>
<name><surname>Chemaly</surname><given-names>R.F.</given-names></name>
<name><surname>Maertens</surname><given-names>J.</given-names></name>
<name><surname>Dadwal</surname><given-names>S.S.</given-names></name>
<name><surname>Duarte</surname><given-names>R.F.</given-names></name>
<name><surname>Haider</surname><given-names>S.</given-names></name>
<name><surname>Ullmann</surname><given-names>A.J.</given-names></name>
<name><surname>Katayama</surname><given-names>Y.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>2433</fpage><lpage>2444</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1706640</pub-id><pub-id pub-id-type="pmid">29211658</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01884"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCrea</surname><given-names>J.B.</given-names></name>
<name><surname>Macha</surname><given-names>S.</given-names></name>
<name><surname>Adedoyin</surname><given-names>A.</given-names></name>
<name><surname>Marshall</surname><given-names>W.</given-names></name>
<name><surname>Menzel</surname><given-names>K.</given-names></name>
<name><surname>Cho</surname><given-names>C.R.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Zhao</surname><given-names>T.</given-names></name>
<name><surname>Levine</surname><given-names>V.</given-names></name>
<name><surname>Kraft</surname><given-names>W.K.</given-names></name>
<etal/>
</person-group><article-title>Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil</article-title><source>J. Clin. Pharmacol.</source><year>2019</year><volume>59</volume><fpage>1331</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1002/jcph.1423</pub-id><pub-id pub-id-type="pmid">30990905</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01884"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duong</surname><given-names>A.</given-names></name>
<name><surname>Sweet</surname><given-names>A.</given-names></name>
<name><surname>Jain</surname><given-names>R.</given-names></name>
<name><surname>Hill</surname><given-names>J.A.</given-names></name>
<name><surname>Pergam</surname><given-names>S.A.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
</person-group><article-title>Clinically significant drug interaction: Letermovir and voriconazole</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>775</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz499</pub-id><pub-id pub-id-type="pmid">31800049</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01884"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Russo</surname><given-names>D.</given-names></name>
<name><surname>Schmitt</surname><given-names>M.</given-names></name>
<name><surname>Pilorge</surname><given-names>S.</given-names></name>
<name><surname>Stelljes</surname><given-names>M.</given-names></name>
<name><surname>Kawakita</surname><given-names>T.</given-names></name>
<name><surname>Teal</surname><given-names>V.L.</given-names></name>
<name><surname>Haber</surname><given-names>B.</given-names></name>
<name><surname>Bopp</surname><given-names>C.</given-names></name>
<name><surname>Dadwal</surname><given-names>S.S.</given-names></name>
<name><surname>Badshah</surname><given-names>C.</given-names></name>
</person-group><article-title>Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Haematol.</source><year>2024</year><volume>11</volume><fpage>e127</fpage><lpage>e135</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(23)00344-7</pub-id><pub-id pub-id-type="pmid">38142695</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01884"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Natori</surname><given-names>Y.</given-names></name>
<name><surname>Humar</surname><given-names>A.</given-names></name>
<name><surname>Husain</surname><given-names>S.</given-names></name>
<name><surname>Rotstein</surname><given-names>C.</given-names></name>
<name><surname>Renner</surname><given-names>E.</given-names></name>
<name><surname>Singer</surname><given-names>L.</given-names></name>
<name><surname>Kim</surname><given-names>S.J.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
</person-group><article-title>Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients</article-title><source>Transplantation</source><year>2017</year><volume>101</volume><fpage>1449</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000001338</pub-id><pub-id pub-id-type="pmid">27467535</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01884"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Razonable</surname><given-names>R.R.</given-names></name>
<name><surname>Humar</surname><given-names>A.</given-names></name>
</person-group><article-title>Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice</article-title><source>Clin. Transplant.</source><year>2019</year><volume>33</volume><fpage>e13512</fpage><pub-id pub-id-type="doi">10.1111/ctr.13512</pub-id><pub-id pub-id-type="pmid">30817026</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01884"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sullivan</surname><given-names>T.</given-names></name>
<name><surname>Brodginski</surname><given-names>A.</given-names></name>
<name><surname>Patel</surname><given-names>G.</given-names></name>
<name><surname>Huprikar</surname><given-names>S.</given-names></name>
</person-group><article-title>The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients</article-title><source>Transplantation</source><year>2015</year><volume>99</volume><fpage>855</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000000386</pub-id><pub-id pub-id-type="pmid">25208322</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01884"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alraddadi</surname><given-names>B.</given-names></name>
<name><surname>Nierenberg</surname><given-names>N.E.</given-names></name>
<name><surname>Price</surname><given-names>L.L.</given-names></name>
<name><surname>Chow</surname><given-names>J.K.</given-names></name>
<name><surname>Poutsiaka</surname><given-names>D.D.</given-names></name>
<name><surname>Rohrer</surname><given-names>R.J.</given-names></name>
<name><surname>Cooper</surname><given-names>J.T.</given-names></name>
<name><surname>Freeman</surname><given-names>R.B.</given-names></name>
<name><surname>Snydman</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Characteristics and outcomes of neutropenia after orthotopic liver transplantation</article-title><source>Liver Transpl.</source><year>2016</year><volume>22</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1002/lt.24332</pub-id><pub-id pub-id-type="pmid">26336061</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01884"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ljungman</surname><given-names>P.</given-names></name>
<name><surname>Deliliers</surname><given-names>G.L.</given-names></name>
<name><surname>Platzbecker</surname><given-names>U.</given-names></name>
<name><surname>Matthes-Martin</surname><given-names>S.</given-names></name>
<name><surname>Bacigalupo</surname><given-names>A.</given-names></name>
<name><surname>Einsele</surname><given-names>H.</given-names></name>
<name><surname>Ullmann</surname><given-names>J.</given-names></name>
<name><surname>Musso</surname><given-names>M.</given-names></name>
<name><surname>Trenschel</surname><given-names>R.</given-names></name>
<name><surname>Ribaud</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>388</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1182/blood.V97.2.388</pub-id><pub-id pub-id-type="pmid">11154213</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01884"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avery</surname><given-names>R.K.</given-names></name>
<name><surname>Alain</surname><given-names>S.</given-names></name>
<name><surname>Alexander</surname><given-names>B.D.</given-names></name>
<name><surname>Blumberg</surname><given-names>E.A.</given-names></name>
<name><surname>Chemaly</surname><given-names>R.F.</given-names></name>
<name><surname>Cordonnier</surname><given-names>C.</given-names></name>
<name><surname>Duarte</surname><given-names>R.F.</given-names></name>
<name><surname>Florescu</surname><given-names>D.F.</given-names></name>
<name><surname>Kamar</surname><given-names>N.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>75</volume><fpage>690</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab988</pub-id><pub-id pub-id-type="pmid">34864943</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01884"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beechar</surname><given-names>V.B.</given-names></name>
<name><surname>Phadke</surname><given-names>V.K.</given-names></name>
<name><surname>Pouch</surname><given-names>S.M.</given-names></name>
<name><surname>Mehta</surname><given-names>A.K.</given-names></name>
<name><surname>Karadkhele</surname><given-names>G.</given-names></name>
<name><surname>Larsen</surname><given-names>C.P.</given-names></name>
<name><surname>Woodworth</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients</article-title><source>Clin. Transplant.</source><year>2024</year><volume>38</volume><fpage>e15480</fpage><pub-id pub-id-type="doi">10.1111/ctr.15480</pub-id><pub-id pub-id-type="pmid">39427300</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01884"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barlam</surname><given-names>T.F.</given-names></name>
<name><surname>Cosgrove</surname><given-names>S.E.</given-names></name>
<name><surname>Abbo</surname><given-names>L.M.</given-names></name>
<name><surname>MacDougall</surname><given-names>C.</given-names></name>
<name><surname>Schuetz</surname><given-names>A.N.</given-names></name>
<name><surname>Septimus</surname><given-names>E.J.</given-names></name>
<name><surname>Srinivasan</surname><given-names>A.</given-names></name>
<name><surname>Dellit</surname><given-names>T.H.</given-names></name>
<name><surname>Falck-Ytter</surname><given-names>Y.T.</given-names></name>
<name><surname>Fishman</surname><given-names>N.O.</given-names></name>
<etal/>
</person-group><article-title>Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>62</volume><fpage>e51</fpage><lpage>e77</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw118</pub-id><pub-id pub-id-type="pmid">27080992</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01884"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asberg</surname><given-names>A.</given-names></name>
<name><surname>Humar</surname><given-names>A.</given-names></name>
<name><surname>Rollag</surname><given-names>H.</given-names></name>
<name><surname>Jardine</surname><given-names>A.G.</given-names></name>
<name><surname>Mouas</surname><given-names>H.</given-names></name>
<name><surname>Pescovitz</surname><given-names>M.D.</given-names></name>
<name><surname>Sgarabotto</surname><given-names>D.</given-names></name>
<name><surname>Tuncer</surname><given-names>M.</given-names></name>
<name><surname>Noronha</surname><given-names>I.L.</given-names></name>
<name><surname>Hartmann</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients</article-title><source>Am. J. Transplant.</source><year>2007</year><volume>7</volume><fpage>2106</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2007.01910.x</pub-id><pub-id pub-id-type="pmid">17640310</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01884"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katada</surname><given-names>Y.</given-names></name>
<name><surname>Umemura</surname><given-names>K.</given-names></name>
<name><surname>Nakagawa</surname><given-names>S.</given-names></name>
<name><surname>Katsube</surname><given-names>Y.</given-names></name>
<name><surname>Tsuda</surname><given-names>M.</given-names></name>
<name><surname>Tanaka</surname><given-names>S.</given-names></name>
<name><surname>Date</surname><given-names>H.</given-names></name>
<name><surname>Nagao</surname><given-names>M.</given-names></name>
<name><surname>Terada</surname><given-names>T.</given-names></name>
</person-group><article-title>A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient</article-title><source>J. Pharm. Health Care Sci.</source><year>2024</year><volume>10</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s40780-024-00352-y</pub-id><pub-id pub-id-type="pmid">38849960</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01884"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>N.</given-names></name>
<name><surname>Athans</surname><given-names>V.</given-names></name>
<name><surname>Neuner</surname><given-names>E.</given-names></name>
<name><surname>Bollinger</surname><given-names>J.</given-names></name>
<name><surname>Spinner</surname><given-names>M.</given-names></name>
<name><surname>Brizendine</surname><given-names>K.</given-names></name>
</person-group><article-title>A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients</article-title><source>Transpl. Infect. Dis.</source><year>2018</year><volume>20</volume><fpage>e12991</fpage><pub-id pub-id-type="doi">10.1111/tid.12991</pub-id><pub-id pub-id-type="pmid">30184302</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01884"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<name><surname>Chin-Hong</surname><given-names>P.</given-names></name>
<name><surname>Kayler</surname><given-names>L.</given-names></name>
<name><surname>Wojciechowski</surname><given-names>D.</given-names></name>
<name><surname>Limaye</surname><given-names>A.P.</given-names></name>
<name><surname>Osama Gaber</surname><given-names>A.</given-names></name>
<name><surname>Ball</surname><given-names>S.</given-names></name>
<name><surname>Mehta</surname><given-names>A.K.</given-names></name>
<name><surname>Cooper</surname><given-names>M.</given-names></name>
<name><surname>Blanchard</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients</article-title><source>Am. J. Transplant.</source><year>2019</year><volume>19</volume><fpage>2505</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1111/ajt.15315</pub-id><pub-id pub-id-type="pmid">30768834</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01884"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<name><surname>Mian</surname><given-names>M.</given-names></name>
<name><surname>Singer</surname><given-names>L.</given-names></name>
<name><surname>Humar</surname><given-names>A.</given-names></name>
</person-group><article-title>An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation</article-title><source>Am. J. Transplant.</source><year>2017</year><volume>17</volume><fpage>2468</fpage><lpage>2473</lpage><pub-id pub-id-type="doi">10.1111/ajt.14347</pub-id><pub-id pub-id-type="pmid">28500691</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01884"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teira</surname><given-names>P.</given-names></name>
<name><surname>Battiwalla</surname><given-names>M.</given-names></name>
<name><surname>Ramanathan</surname><given-names>M.</given-names></name>
<name><surname>Barrett</surname><given-names>A.J.</given-names></name>
<name><surname>Ahn</surname><given-names>K.W.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Green</surname><given-names>J.S.</given-names></name>
<name><surname>Saad</surname><given-names>A.</given-names></name>
<name><surname>Antin</surname><given-names>J.H.</given-names></name>
<name><surname>Savani</surname><given-names>B.N.</given-names></name>
<etal/>
</person-group><article-title>Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: A CIBMTR analysis</article-title><source>Blood</source><year>2016</year><volume>127</volume><fpage>2427</fpage><lpage>2438</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-11-679639</pub-id><pub-id pub-id-type="pmid">26884374</pub-id>
</element-citation></ref><ref id="B40-viruses-16-01884"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hakki</surname><given-names>M.</given-names></name>
<name><surname>Aitken</surname><given-names>S.L.</given-names></name>
<name><surname>Danziger-Isakov</surname><given-names>L.</given-names></name>
<name><surname>Michaels</surname><given-names>M.G.</given-names></name>
<name><surname>Carpenter</surname><given-names>P.A.</given-names></name>
<name><surname>Chemaly</surname><given-names>R.F.</given-names></name>
<name><surname>Papanicolaou</surname><given-names>G.A.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
<name><surname>Marty</surname><given-names>F.M.</given-names></name>
</person-group><article-title>American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation</article-title><source>Transplant. Cell Ther.</source><year>2021</year><volume>27</volume><fpage>707</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/j.jtct.2021.05.001</pub-id><pub-id pub-id-type="pmid">34452721</pub-id>
</element-citation></ref><ref id="B41-viruses-16-01884"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jakharia</surname><given-names>N.</given-names></name>
<name><surname>Howard</surname><given-names>D.</given-names></name>
<name><surname>Riedel</surname><given-names>D.J.</given-names></name>
</person-group><article-title>CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies</article-title><source>Curr. Treat. Options Infect. Dis.</source><year>2021</year><volume>13</volume><fpage>123</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1007/s40506-021-00253-w</pub-id><pub-id pub-id-type="pmid">34305463</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01884"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>C.A.</given-names></name>
<name><surname>Palen</surname><given-names>L.</given-names></name>
<name><surname>Su</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Gennarelli</surname><given-names>R.L.</given-names></name>
<name><surname>Perales</surname><given-names>M.A.</given-names></name>
<name><surname>Cohen</surname><given-names>N.</given-names></name>
<name><surname>Papanicolaou</surname><given-names>G.A.</given-names></name>
<name><surname>Shah</surname><given-names>G.L.</given-names></name>
<name><surname>Seo</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation</article-title><source>Transplant. Cell Ther.</source><year>2024</year><volume>30</volume><fpage>792.e1</fpage><lpage>792.e12</lpage><pub-id pub-id-type="doi">10.1016/j.jtct.2024.05.021</pub-id><pub-id pub-id-type="pmid">38838781</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01884"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chemaly</surname><given-names>R.F.</given-names></name>
<name><surname>El Haddad</surname><given-names>L.</given-names></name>
<name><surname>Winston</surname><given-names>D.J.</given-names></name>
<name><surname>Rowley</surname><given-names>S.D.</given-names></name>
<name><surname>Mulane</surname><given-names>K.M.</given-names></name>
<name><surname>Chandrasekar</surname><given-names>P.</given-names></name>
<name><surname>Avery</surname><given-names>R.K.</given-names></name>
<name><surname>Hari</surname><given-names>P.</given-names></name>
<name><surname>Peggs</surname><given-names>K.S.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>71</volume><fpage>2365</fpage><lpage>2374</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz1210</pub-id><pub-id pub-id-type="pmid">32076709</pub-id>
</element-citation></ref><ref id="B44-viruses-16-01884"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barkam</surname><given-names>C.</given-names></name>
<name><surname>Kamal</surname><given-names>H.</given-names></name>
<name><surname>Dammann</surname><given-names>E.</given-names></name>
<name><surname>Diedrich</surname><given-names>H.</given-names></name>
<name><surname>Buchholz</surname><given-names>S.</given-names></name>
<name><surname>Eder</surname><given-names>M.</given-names></name>
<name><surname>Krauter</surname><given-names>J.</given-names></name>
<name><surname>Ganser</surname><given-names>A.</given-names></name>
<name><surname>Stadler</surname><given-names>M.</given-names></name>
</person-group><article-title>Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation</article-title><source>Bone Marrow Res.</source><year>2012</year><volume>2012</volume><fpage>874601</fpage><pub-id pub-id-type="doi">10.1155/2012/874601</pub-id><pub-id pub-id-type="pmid">23243512</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01884"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reusser</surname><given-names>P.</given-names></name>
<name><surname>Einsele</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Volin</surname><given-names>L.</given-names></name>
<name><surname>Rovira</surname><given-names>M.</given-names></name>
<name><surname>Engelhard</surname><given-names>D.</given-names></name>
<name><surname>Finke</surname><given-names>J.</given-names></name>
<name><surname>Cordonnier</surname><given-names>C.</given-names></name>
<name><surname>Link</surname><given-names>H.</given-names></name>
<name><surname>Ljungman</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1182/blood.V99.4.1159</pub-id><pub-id pub-id-type="pmid">11830461</pub-id>
</element-citation></ref><ref id="B46-viruses-16-01884"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruiz-Camps</surname><given-names>I.</given-names></name>
<name><surname>Len</surname><given-names>O.</given-names></name>
<name><surname>de la Camara</surname><given-names>R.</given-names></name>
<name><surname>Gurgui</surname><given-names>M.</given-names></name>
<name><surname>Martino</surname><given-names>R.</given-names></name>
<name><surname>Jarque</surname><given-names>I.</given-names></name>
<name><surname>Barrenetxea</surname><given-names>C.</given-names></name>
<name><surname>Diaz de Heredia</surname><given-names>C.</given-names></name>
<name><surname>Batlle</surname><given-names>M.</given-names></name>
<name><surname>Rovira</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients</article-title><source>Antivir. Ther.</source><year>2011</year><volume>16</volume><fpage>951</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.3851/IMP1858</pub-id><pub-id pub-id-type="pmid">22024510</pub-id>
</element-citation></ref><ref id="B47-viruses-16-01884"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Einsele</surname><given-names>H.</given-names></name>
<name><surname>Reusser</surname><given-names>P.</given-names></name>
<name><surname>Bornhauser</surname><given-names>M.</given-names></name>
<name><surname>Kalhs</surname><given-names>P.</given-names></name>
<name><surname>Ehninger</surname><given-names>G.</given-names></name>
<name><surname>Hebart</surname><given-names>H.</given-names></name>
<name><surname>Chalandon</surname><given-names>Y.</given-names></name>
<name><surname>Kroger</surname><given-names>N.</given-names></name>
<name><surname>Hertenstein</surname><given-names>B.</given-names></name>
<name><surname>Rohde</surname><given-names>F.</given-names></name>
</person-group><article-title>Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>3002</fpage><lpage>3008</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-09-3786</pub-id><pub-id pub-id-type="pmid">16352807</pub-id>
</element-citation></ref><ref id="B48-viruses-16-01884"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papanicolaou</surname><given-names>G.A.</given-names></name>
<name><surname>Avery</surname><given-names>R.K.</given-names></name>
<name><surname>Cordonnier</surname><given-names>C.</given-names></name>
<name><surname>Duarte</surname><given-names>R.F.</given-names></name>
<name><surname>Haider</surname><given-names>S.</given-names></name>
<name><surname>Maertens</surname><given-names>J.</given-names></name>
<name><surname>Peggs</surname><given-names>K.S.</given-names></name>
<name><surname>Solano</surname><given-names>C.</given-names></name>
<name><surname>Young</surname><given-names>J.H.</given-names></name>
<name><surname>Fournier</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>78</volume><fpage>562</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1093/cid/ciad709</pub-id><pub-id pub-id-type="pmid">38036487</pub-id>
</element-citation></ref><ref id="B49-viruses-16-01884"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schultz</surname><given-names>B.G.</given-names></name>
<name><surname>Bullano</surname><given-names>M.</given-names></name>
<name><surname>Paratane</surname><given-names>D.</given-names></name>
<name><surname>Rajagopalan</surname><given-names>K.</given-names></name>
</person-group><article-title>Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based study</article-title><source>Transpl. Infect. Dis.</source><year>2024</year><volume>26</volume><fpage>e14216</fpage><pub-id pub-id-type="doi">10.1111/tid.14216</pub-id><pub-id pub-id-type="pmid">38221739</pub-id>
</element-citation></ref><ref id="B50-viruses-16-01884"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Withers</surname><given-names>B.</given-names></name>
<name><surname>Blyth</surname><given-names>E.</given-names></name>
<name><surname>Clancy</surname><given-names>L.E.</given-names></name>
<name><surname>Yong</surname><given-names>A.</given-names></name>
<name><surname>Fraser</surname><given-names>C.</given-names></name>
<name><surname>Burgess</surname><given-names>J.</given-names></name>
<name><surname>Simms</surname><given-names>R.</given-names></name>
<name><surname>Brown</surname><given-names>R.</given-names></name>
<name><surname>Kliman</surname><given-names>D.</given-names></name>
<name><surname>Dubosq</surname><given-names>M.C.</given-names></name>
<etal/>
</person-group><article-title>Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells</article-title><source>Blood Adv.</source><year>2017</year><volume>1</volume><fpage>2193</fpage><lpage>2205</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2017010223</pub-id><pub-id pub-id-type="pmid">29296867</pub-id>
</element-citation></ref><ref id="B51-viruses-16-01884"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Withers</surname><given-names>B.</given-names></name>
<name><surname>Clancy</surname><given-names>L.</given-names></name>
<name><surname>Burgess</surname><given-names>J.</given-names></name>
<name><surname>Simms</surname><given-names>R.</given-names></name>
<name><surname>Brown</surname><given-names>R.</given-names></name>
<name><surname>Micklethwaite</surname><given-names>K.</given-names></name>
<name><surname>Blyth</surname><given-names>E.</given-names></name>
<name><surname>Gottlieb</surname><given-names>D.</given-names></name>
</person-group><article-title>Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program</article-title><source>Biol. Blood Marrow Transplant.</source><year>2018</year><volume>24</volume><fpage>2433</fpage><lpage>2442</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2018.08.024</pub-id><pub-id pub-id-type="pmid">30172015</pub-id>
</element-citation></ref><ref id="B52-viruses-16-01884"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Reilly</surname><given-names>R.J.</given-names></name>
<name><surname>Prockop</surname><given-names>S.</given-names></name>
<name><surname>Hasan</surname><given-names>A.N.</given-names></name>
<name><surname>Koehne</surname><given-names>G.</given-names></name>
<name><surname>Doubrovina</surname><given-names>E.</given-names></name>
</person-group><article-title>Virus-specific T-cell banks for &#x02018;off the shelf&#x02019; adoptive therapy of refractory infections</article-title><source>Bone Marrow Transplant.</source><year>2016</year><volume>51</volume><fpage>1163</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1038/bmt.2016.17</pub-id><pub-id pub-id-type="pmid">27042851</pub-id>
</element-citation></ref><ref id="B53-viruses-16-01884"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El Chaer</surname><given-names>F.</given-names></name>
<name><surname>Kaul</surname><given-names>D.R.</given-names></name>
<name><surname>Englund</surname><given-names>J.A.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
<name><surname>Batista</surname><given-names>M.V.</given-names></name>
<name><surname>Seo</surname><given-names>S.K.</given-names></name>
<name><surname>Carpenter</surname><given-names>P.A.</given-names></name>
<name><surname>Navarro</surname><given-names>D.</given-names></name>
<name><surname>Hirsch</surname><given-names>H.H.</given-names></name>
<name><surname>Ison</surname><given-names>M.G.</given-names></name>
<etal/>
</person-group><article-title>American Society of Transplantation and Cellular Therapy Series: #7&#x02014;Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients</article-title><source>Transplant. Cell Ther.</source><year>2023</year><volume>29</volume><fpage>730</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1016/j.jtct.2023.09.018</pub-id><pub-id pub-id-type="pmid">37783338</pub-id>
</element-citation></ref><ref id="B54-viruses-16-01884"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manuel</surname><given-names>O.</given-names></name>
<name><surname>Estabrook</surname><given-names>M.</given-names></name>
<collab>American Society of Transplantation Infectious Diseases Community of Practice</collab>
</person-group><article-title>RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice</article-title><source>Clin. Transplant.</source><year>2019</year><volume>33</volume><fpage>e13511</fpage><pub-id pub-id-type="doi">10.1111/ctr.13511</pub-id><pub-id pub-id-type="pmid">30817023</pub-id>
</element-citation></ref><ref id="B55-viruses-16-01884"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y.J.</given-names></name>
<name><surname>Guthrie</surname><given-names>K.A.</given-names></name>
<name><surname>Waghmare</surname><given-names>A.</given-names></name>
<name><surname>Walsh</surname><given-names>E.E.</given-names></name>
<name><surname>Falsey</surname><given-names>A.R.</given-names></name>
<name><surname>Kuypers</surname><given-names>J.</given-names></name>
<name><surname>Cent</surname><given-names>A.</given-names></name>
<name><surname>Englund</surname><given-names>J.A.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
</person-group><article-title>Respiratory syncytial virus in hematopoietic cell transplant recipients: Factors determining progression to lower respiratory tract disease</article-title><source>J. Infect. Dis.</source><year>2014</year><volume>209</volume><fpage>1195</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit832</pub-id><pub-id pub-id-type="pmid">24368837</pub-id>
</element-citation></ref><ref id="B56-viruses-16-01884"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Zwart</surname><given-names>A.</given-names></name>
<name><surname>Riezebos-Brilman</surname><given-names>A.</given-names></name>
<name><surname>Lunter</surname><given-names>G.</given-names></name>
<name><surname>Vonk</surname><given-names>J.</given-names></name>
<name><surname>Glanville</surname><given-names>A.R.</given-names></name>
<name><surname>Gottlieb</surname><given-names>J.</given-names></name>
<name><surname>Permpalung</surname><given-names>N.</given-names></name>
<name><surname>Kerstjens</surname><given-names>H.</given-names></name>
<name><surname>Alffenaar</surname><given-names>J.W.</given-names></name>
<name><surname>Verschuuren</surname><given-names>E.</given-names></name>
</person-group><article-title>Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>74</volume><fpage>2252</fpage><lpage>2260</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab969</pub-id><pub-id pub-id-type="pmid">35022697</pub-id>
</element-citation></ref><ref id="B57-viruses-16-01884"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Schiff</surname><given-names>E.R.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Lee</surname><given-names>W.M.</given-names></name>
<name><surname>Rustgi</surname><given-names>V.K.</given-names></name>
<name><surname>Goodman</surname><given-names>Z.D.</given-names></name>
<name><surname>Ling</surname><given-names>M.H.</given-names></name>
<name><surname>Cort</surname><given-names>S.</given-names></name>
<name><surname>Albrecht</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group</article-title><source>N. Engl. J. Med.</source><year>1998</year><volume>339</volume><fpage>1485</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1056/NEJM199811193392101</pub-id><pub-id pub-id-type="pmid">9819446</pub-id>
</element-citation></ref><ref id="B58-viruses-16-01884"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>D.P.</given-names></name>
<name><surname>Ghantoji</surname><given-names>S.S.</given-names></name>
<name><surname>Ariza-Heredia</surname><given-names>E.J.</given-names></name>
<name><surname>Shah</surname><given-names>J.N.</given-names></name>
<name><surname>El Taoum</surname><given-names>K.K.</given-names></name>
<name><surname>Shah</surname><given-names>P.K.</given-names></name>
<name><surname>Nesher</surname><given-names>L.</given-names></name>
<name><surname>Hosing</surname><given-names>C.</given-names></name>
<name><surname>Rondon</surname><given-names>G.</given-names></name>
<name><surname>Champlin</surname><given-names>R.E.</given-names></name>
<etal/>
</person-group><article-title>Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections</article-title><source>Blood</source><year>2014</year><volume>123</volume><fpage>3263</fpage><lpage>3268</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-12-541359</pub-id><pub-id pub-id-type="pmid">24700783</pub-id>
</element-citation></ref><ref id="B59-viruses-16-01884"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>D.P.</given-names></name>
<name><surname>Ghantoji</surname><given-names>S.S.</given-names></name>
<name><surname>Shah</surname><given-names>J.N.</given-names></name>
<name><surname>El Taoum</surname><given-names>K.K.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Popat</surname><given-names>U.</given-names></name>
<name><surname>Hosing</surname><given-names>C.</given-names></name>
<name><surname>Rondon</surname><given-names>G.</given-names></name>
<name><surname>Tarrand</surname><given-names>J.J.</given-names></name>
<name><surname>Champlin</surname><given-names>R.E.</given-names></name>
<etal/>
</person-group><article-title>Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections</article-title><source>J. Antimicrob. Chemother.</source><year>2013</year><volume>68</volume><fpage>1872</fpage><lpage>1880</lpage><pub-id pub-id-type="doi">10.1093/jac/dkt111</pub-id><pub-id pub-id-type="pmid">23572228</pub-id>
</element-citation></ref><ref id="B60-viruses-16-01884"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>V.</given-names></name>
<name><surname>Dhillon</surname><given-names>G.S.</given-names></name>
<name><surname>Weill</surname><given-names>D.</given-names></name>
</person-group><article-title>A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients</article-title><source>Transpl. Infect. Dis.</source><year>2010</year><volume>12</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3062.2009.00453.x</pub-id><pub-id pub-id-type="pmid">19761558</pub-id>
</element-citation></ref><ref id="B61-viruses-16-01884"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
<name><surname>Englund</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Miller</surname><given-names>C.</given-names></name>
<name><surname>Cross</surname><given-names>A.</given-names></name>
<name><surname>Fernandez</surname><given-names>H.</given-names></name>
<name><surname>Kuypers</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Gnann</surname><given-names>J.</given-names></name>
<name><surname>Whitley</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients</article-title><source>Clin. Infect. Dis.</source><year>2007</year><volume>44</volume><fpage>245</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1086/509930</pub-id><pub-id pub-id-type="pmid">17173225</pub-id>
</element-citation></ref><ref id="B62-viruses-16-01884"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghosh</surname><given-names>S.</given-names></name>
<name><surname>Champlin</surname><given-names>R.E.</given-names></name>
<name><surname>Englund</surname><given-names>J.</given-names></name>
<name><surname>Giralt</surname><given-names>S.A.</given-names></name>
<name><surname>Rolston</surname><given-names>K.</given-names></name>
<name><surname>Raad</surname><given-names>I.</given-names></name>
<name><surname>Jacobson</surname><given-names>K.</given-names></name>
<name><surname>Neumann</surname><given-names>J.</given-names></name>
<name><surname>Ippoliti</surname><given-names>C.</given-names></name>
<name><surname>Mallik</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin</article-title><source>Bone Marrow Transplant.</source><year>2000</year><volume>25</volume><fpage>751</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1038/sj.bmt.1702228</pub-id><pub-id pub-id-type="pmid">10745261</pub-id>
</element-citation></ref><ref id="B63-viruses-16-01884"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foolad</surname><given-names>F.</given-names></name>
<name><surname>Aitken</surname><given-names>S.L.</given-names></name>
<name><surname>Shigle</surname><given-names>T.L.</given-names></name>
<name><surname>Prayag</surname><given-names>A.</given-names></name>
<name><surname>Ghantoji</surname><given-names>S.</given-names></name>
<name><surname>Ariza-Heredia</surname><given-names>E.</given-names></name>
<name><surname>Chemaly</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients</article-title><source>Clin. Infect. Dis.</source><year>2019</year><volume>68</volume><fpage>1641</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy760</pub-id><pub-id pub-id-type="pmid">30202920</pub-id>
</element-citation></ref><ref id="B64-viruses-16-01884"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burrows</surname><given-names>F.S.</given-names></name>
<name><surname>Carlos</surname><given-names>L.M.</given-names></name>
<name><surname>Benzimra</surname><given-names>M.</given-names></name>
<name><surname>Marriott</surname><given-names>D.J.</given-names></name>
<name><surname>Havryk</surname><given-names>A.P.</given-names></name>
<name><surname>Plit</surname><given-names>M.L.</given-names></name>
<name><surname>Malouf</surname><given-names>M.A.</given-names></name>
<name><surname>Glanville</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency</article-title><source>J. Heart Lung Transplant.</source><year>2015</year><volume>34</volume><fpage>958</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2015.01.009</pub-id><pub-id pub-id-type="pmid">25753833</pub-id>
</element-citation></ref><ref id="B65-viruses-16-01884"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melgar</surname><given-names>M.</given-names></name>
<name><surname>Britton</surname><given-names>A.</given-names></name>
<name><surname>Roper</surname><given-names>L.E.</given-names></name>
<name><surname>Talbot</surname><given-names>H.K.</given-names></name>
<name><surname>Long</surname><given-names>S.S.</given-names></name>
<name><surname>Kotton</surname><given-names>C.N.</given-names></name>
<name><surname>Havers</surname><given-names>F.P.</given-names></name>
</person-group><article-title>Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices&#x02014;United States, 2023</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2023</year><volume>72</volume><fpage>793</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7229a4</pub-id><pub-id pub-id-type="pmid">37471262</pub-id>
</element-citation></ref><ref id="B66-viruses-16-01884"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papi</surname><given-names>A.</given-names></name>
<name><surname>Ison</surname><given-names>M.G.</given-names></name>
<name><surname>Langley</surname><given-names>J.M.</given-names></name>
<name><surname>Lee</surname><given-names>D.G.</given-names></name>
<name><surname>Leroux-Roels</surname><given-names>I.</given-names></name>
<name><surname>Martinon-Torres</surname><given-names>F.</given-names></name>
<name><surname>Schwarz</surname><given-names>T.F.</given-names></name>
<name><surname>van Zyl-Smit</surname><given-names>R.N.</given-names></name>
<name><surname>Campora</surname><given-names>L.</given-names></name>
<name><surname>Dezutter</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>595</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2209604</pub-id><pub-id pub-id-type="pmid">36791160</pub-id>
</element-citation></ref><ref id="B67-viruses-16-01884"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walsh</surname><given-names>E.E.</given-names></name>
<name><surname>Perez Marc</surname><given-names>G.</given-names></name>
<name><surname>Zareba</surname><given-names>A.M.</given-names></name>
<name><surname>Falsey</surname><given-names>A.R.</given-names></name>
<name><surname>Jiang</surname><given-names>Q.</given-names></name>
<name><surname>Patton</surname><given-names>M.</given-names></name>
<name><surname>Polack</surname><given-names>F.P.</given-names></name>
<name><surname>Llapur</surname><given-names>C.</given-names></name>
<name><surname>Doreski</surname><given-names>P.A.</given-names></name>
<name><surname>Ilangovan</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>1465</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2213836</pub-id><pub-id pub-id-type="pmid">37018468</pub-id>
</element-citation></ref><ref id="B68-viruses-16-01884"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>E.</given-names></name>
<name><surname>Goswami</surname><given-names>J.</given-names></name>
<name><surname>Baqui</surname><given-names>A.H.</given-names></name>
<name><surname>Doreski</surname><given-names>P.A.</given-names></name>
<name><surname>Perez-Marc</surname><given-names>G.</given-names></name>
<name><surname>Zaman</surname><given-names>K.</given-names></name>
<name><surname>Monroy</surname><given-names>J.</given-names></name>
<name><surname>Duncan</surname><given-names>C.J.A.</given-names></name>
<name><surname>Ujiie</surname><given-names>M.</given-names></name>
<name><surname>Ramet</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>2233</fpage><lpage>2244</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2307079</pub-id><pub-id pub-id-type="pmid">38091530</pub-id>
</element-citation></ref><ref id="B69-viruses-16-01884"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kolla</surname><given-names>E.</given-names></name>
<name><surname>Weill</surname><given-names>A.</given-names></name>
<name><surname>Zaidan</surname><given-names>M.</given-names></name>
<name><surname>De Martin</surname><given-names>E.</given-names></name>
<name><surname>Colin De Verdiere</surname><given-names>S.</given-names></name>
<name><surname>Semenzato</surname><given-names>L.</given-names></name>
<name><surname>Zureik</surname><given-names>M.</given-names></name>
<name><surname>Grimaldi</surname><given-names>L.</given-names></name>
</person-group><article-title>COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive Therapy</article-title><source>JAMA Netw. Open</source><year>2023</year><volume>6</volume><fpage>e2342006</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.42006</pub-id><pub-id pub-id-type="pmid">37934496</pub-id>
</element-citation></ref><ref id="B70-viruses-16-01884"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solera</surname><given-names>J.T.</given-names></name>
<name><surname>Arbol</surname><given-names>B.G.</given-names></name>
<name><surname>Mittal</surname><given-names>A.</given-names></name>
<name><surname>Hall</surname><given-names>V.</given-names></name>
<name><surname>Marinelli</surname><given-names>T.</given-names></name>
<name><surname>Bahinskaya</surname><given-names>I.</given-names></name>
<name><surname>Selzner</surname><given-names>N.</given-names></name>
<name><surname>McDonald</surname><given-names>M.</given-names></name>
<name><surname>Schiff</surname><given-names>J.</given-names></name>
<name><surname>Sidhu</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023</article-title><source>Am. J. Transplant.</source><year>2024</year><volume>24</volume><fpage>1303</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1016/j.ajt.2024.03.011</pub-id><pub-id pub-id-type="pmid">38499087</pub-id>
</element-citation></ref><ref id="B71-viruses-16-01884"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>E.A.</given-names></name>
<name><surname>Krantz</surname><given-names>E.M.</given-names></name>
<name><surname>McCulloch</surname><given-names>D.J.</given-names></name>
<name><surname>Wilson</surname><given-names>M.H.</given-names></name>
<name><surname>Tverdek</surname><given-names>F.</given-names></name>
<name><surname>Kassamali Escobar</surname><given-names>Z.</given-names></name>
<name><surname>Drucker</surname><given-names>D.</given-names></name>
<name><surname>Sanchez</surname><given-names>E.</given-names></name>
<name><surname>Ueda Oshima</surname><given-names>M.</given-names></name>
<name><surname>Mielcarek</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics</article-title><source>Transplant. Cell Ther.</source><year>2024</year><volume>30</volume><fpage>1108.e1101</fpage><lpage>1108.e1111</lpage><pub-id pub-id-type="doi">10.1016/j.jtct.2024.09.019</pub-id><pub-id pub-id-type="pmid">39321924</pub-id>
</element-citation></ref><ref id="B72-viruses-16-01884"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamura</surname><given-names>T.J.</given-names></name>
<name><surname>Choudhary</surname><given-names>M.C.</given-names></name>
<name><surname>Deo</surname><given-names>R.</given-names></name>
<name><surname>Yousuf</surname><given-names>F.</given-names></name>
<name><surname>Gomez</surname><given-names>A.N.</given-names></name>
<name><surname>Edelstein</surname><given-names>G.E.</given-names></name>
<name><surname>Boucau</surname><given-names>J.</given-names></name>
<name><surname>Glover</surname><given-names>O.T.</given-names></name>
<name><surname>Barry</surname><given-names>M.</given-names></name>
<name><surname>Gilbert</surname><given-names>R.F.</given-names></name>
<etal/>
</person-group><article-title>Emerging SARS-CoV-2 Resistance After Antiviral Treatment</article-title><source>JAMA Netw. Open</source><year>2024</year><volume>7</volume><fpage>e2435431</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.35431</pub-id><pub-id pub-id-type="pmid">39320890</pub-id>
</element-citation></ref><ref id="B73-viruses-16-01884"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solera</surname><given-names>J.T.</given-names></name>
<name><surname>Arbol</surname><given-names>B.G.</given-names></name>
<name><surname>Bahinskaya</surname><given-names>I.</given-names></name>
<name><surname>Marks</surname><given-names>N.</given-names></name>
<name><surname>Humar</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
</person-group><article-title>Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave</article-title><source>Am. J. Transplant.</source><year>2023</year><volume>23</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1111/ajt.17199</pub-id><pub-id pub-id-type="pmid">36148607</pub-id>
</element-citation></ref><ref id="B74-viruses-16-01884"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhand</surname><given-names>A.</given-names></name>
<name><surname>Okumura</surname><given-names>K.</given-names></name>
<name><surname>Ohira</surname><given-names>S.</given-names></name>
<name><surname>Kapur</surname><given-names>R.</given-names></name>
<name><surname>Wolfe</surname><given-names>K.</given-names></name>
<name><surname>Nishida</surname><given-names>S.</given-names></name>
</person-group><article-title>Molnupiravir for Treatment of COVID-19 in Solid Organ Transplant Recipients</article-title><source>Transplantation</source><year>2023</year><volume>107</volume><fpage>e182</fpage><lpage>e183</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000004588</pub-id><pub-id pub-id-type="pmid">36959161</pub-id>
</element-citation></ref><ref id="B75-viruses-16-01884"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Belden</surname><given-names>K.A.</given-names></name>
<name><surname>Yeager</surname><given-names>S.</given-names></name>
<name><surname>Schulte</surname><given-names>J.</given-names></name>
<name><surname>Cantarin</surname><given-names>M.P.M.</given-names></name>
<name><surname>Moss</surname><given-names>S.</given-names></name>
<name><surname>Royer</surname><given-names>T.</given-names></name>
<name><surname>Coppock</surname><given-names>D.</given-names></name>
</person-group><article-title>Saving lives with nirmatrelvir/ritonavir one transplant patient at a time</article-title><source>Transpl. Infect. Dis.</source><year>2023</year><volume>25</volume><fpage>e14037</fpage><pub-id pub-id-type="doi">10.1111/tid.14037</pub-id><pub-id pub-id-type="pmid">36847419</pub-id>
</element-citation></ref><ref id="B76-viruses-16-01884"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhimraj</surname><given-names>A.</given-names></name>
<name><surname>Morgan</surname><given-names>R.L.</given-names></name>
<name><surname>Shumaker</surname><given-names>A.H.</given-names></name>
<name><surname>Lavergne</surname><given-names>V.</given-names></name>
<name><surname>Baden</surname><given-names>L.</given-names></name>
<name><surname>Cheng</surname><given-names>V.C.</given-names></name>
<name><surname>Edwards</surname><given-names>K.M.</given-names></name>
<name><surname>Gandhi</surname><given-names>R.</given-names></name>
<name><surname>Muller</surname><given-names>W.J.</given-names></name>
<name><surname>O&#x02019;Horo</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19</article-title><source>Clin. Infect. Dis.</source><year>2024</year><pub-id pub-id-type="doi">10.1093/cid/ciaa478</pub-id></element-citation></ref><ref id="B77-viruses-16-01884"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dioverti</surname><given-names>V.</given-names></name>
<name><surname>Boghdadly</surname><given-names>Z.E.</given-names></name>
<name><surname>Shahid</surname><given-names>Z.</given-names></name>
<name><surname>Waghmare</surname><given-names>A.</given-names></name>
<name><surname>Abidi</surname><given-names>M.Z.</given-names></name>
<name><surname>Pergam</surname><given-names>S.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
<name><surname>Dadwal</surname><given-names>S.</given-names></name>
<name><surname>Kamboj</surname><given-names>M.</given-names></name>
<name><surname>Seo</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)</article-title><source>Transplant. Cell. Ther.</source><year>2022</year><volume>28</volume><fpage>810</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1016/j.jtct.2022.09.002</pub-id><pub-id pub-id-type="pmid">36103987</pub-id>
</element-citation></ref><ref id="B78-viruses-16-01884"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herrera</surname><given-names>S.</given-names></name>
<name><surname>Aguado</surname><given-names>J.M.</given-names></name>
<name><surname>Candel</surname><given-names>F.J.</given-names></name>
<name><surname>Cordero</surname><given-names>E.</given-names></name>
<name><surname>Dominguez-Gil</surname><given-names>B.</given-names></name>
<name><surname>Fernandez-Ruiz</surname><given-names>M.</given-names></name>
<name><surname>Los Arcos</surname><given-names>I.</given-names></name>
<name><surname>Len</surname><given-names>O.</given-names></name>
<name><surname>Marcos</surname><given-names>M.A.</given-names></name>
<name><surname>Munez</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients</article-title><source>Transplant. Rev.</source><year>2023</year><volume>37</volume><fpage>100788</fpage><pub-id pub-id-type="doi">10.1016/j.trre.2023.100788</pub-id></element-citation></ref><ref id="B79-viruses-16-01884"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>D.H.</given-names></name>
<name><surname>Zuckerman</surname><given-names>R.A.</given-names></name>
<collab>AST Infectious Diseases Community of Practice</collab>
</person-group><article-title>Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice</article-title><source>Clin. Transplant.</source><year>2019</year><volume>33</volume><fpage>e13526</fpage><pub-id pub-id-type="doi">10.1111/ctr.13526</pub-id><pub-id pub-id-type="pmid">30859647</pub-id>
</element-citation></ref><ref id="B80-viruses-16-01884"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erard</surname><given-names>V.</given-names></name>
<name><surname>Wald</surname><given-names>A.</given-names></name>
<name><surname>Corey</surname><given-names>L.</given-names></name>
<name><surname>Leisenring</surname><given-names>W.M.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
</person-group><article-title>Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: Impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease</article-title><source>J. Infect. Dis.</source><year>2007</year><volume>196</volume><fpage>266</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1086/518938</pub-id><pub-id pub-id-type="pmid">17570114</pub-id>
</element-citation></ref><ref id="B81-viruses-16-01884"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baden</surname><given-names>L.R.</given-names></name>
<name><surname>Swaminathan</surname><given-names>S.</given-names></name>
<name><surname>Angarone</surname><given-names>M.</given-names></name>
<name><surname>Blouin</surname><given-names>G.</given-names></name>
<name><surname>Camins</surname><given-names>B.C.</given-names></name>
<name><surname>Casper</surname><given-names>C.</given-names></name>
<name><surname>Cooper</surname><given-names>B.</given-names></name>
<name><surname>Dubberke</surname><given-names>E.R.</given-names></name>
<name><surname>Engemann</surname><given-names>A.M.</given-names></name>
<name><surname>Freifeld</surname><given-names>A.G.</given-names></name>
<etal/>
</person-group><article-title>Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology</article-title><source>J. Natl. Compr. Canc Netw.</source><year>2016</year><volume>14</volume><fpage>882</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2016.0093</pub-id><pub-id pub-id-type="pmid">27407129</pub-id>
</element-citation></ref><ref id="B82-viruses-16-01884"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Broadhurst</surname><given-names>M.J.</given-names></name>
<name><surname>Dujari</surname><given-names>S.</given-names></name>
<name><surname>Budvytiene</surname><given-names>I.</given-names></name>
<name><surname>Pinsky</surname><given-names>B.A.</given-names></name>
<name><surname>Gold</surname><given-names>C.A.</given-names></name>
<name><surname>Banaei</surname><given-names>N.</given-names></name>
</person-group><article-title>Utilization, Yield, and Accuracy of the FilmArray Meningitis/Encephalitis Panel with Diagnostic Stewardship and Testing Algorithm</article-title><source>J. Clin. Microbiol.</source><year>2020</year><volume>58</volume><elocation-id>e00311-20</elocation-id><pub-id pub-id-type="doi">10.1128/JCM.00311-20</pub-id><pub-id pub-id-type="pmid">32493787</pub-id>
</element-citation></ref><ref id="B83-viruses-16-01884"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Markovich</surname><given-names>K.</given-names></name>
<name><surname>Wingler</surname><given-names>M.J.B.</given-names></name>
<name><surname>Stover</surname><given-names>K.R.</given-names></name>
<name><surname>Barber</surname><given-names>K.E.</given-names></name>
<name><surname>Wagner</surname><given-names>J.L.</given-names></name>
<name><surname>Cretella</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Analysis of the Clinical Impact of the BioFire FilmArray Meningitis Encephalitis Panel on Antimicrobial Use and Duration of Therapy at an Academic Medical Center</article-title><source>Diseases</source><year>2022</year><volume>10</volume><elocation-id>110</elocation-id><pub-id pub-id-type="doi">10.3390/diseases10040110</pub-id><pub-id pub-id-type="pmid">36412604</pub-id>
</element-citation></ref><ref id="B84-viruses-16-01884"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tansarli</surname><given-names>G.S.</given-names></name>
<name><surname>Chapin</surname><given-names>K.C.</given-names></name>
</person-group><article-title>Diagnostic test accuracy of the BioFire(R) FilmArray(R) meningitis/encephalitis panel: A systematic review and meta-analysis</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><volume>26</volume><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2019.11.016</pub-id><pub-id pub-id-type="pmid">31760115</pub-id>
</element-citation></ref><ref id="B85-viruses-16-01884"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Styczynski</surname><given-names>J.</given-names></name>
<name><surname>van der Velden</surname><given-names>W.</given-names></name>
<name><surname>Fox</surname><given-names>C.P.</given-names></name>
<name><surname>Engelhard</surname><given-names>D.</given-names></name>
<name><surname>de la Camara</surname><given-names>R.</given-names></name>
<name><surname>Cordonnier</surname><given-names>C.</given-names></name>
<name><surname>Ljungman</surname><given-names>P.</given-names></name>
</person-group><article-title>Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines</article-title><source>Haematologica</source><year>2016</year><volume>101</volume><fpage>803</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.3324/haematol.2016.144428</pub-id><pub-id pub-id-type="pmid">27365460</pub-id>
</element-citation></ref><ref id="B86-viruses-16-01884"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>U.D.</given-names></name>
<name><surname>Preiksaitis</surname><given-names>J.K.</given-names></name>
<collab>AST Infectious Diseases Community of Practice</collab>
</person-group><article-title>Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice</article-title><source>Clin. Transplant.</source><year>2019</year><volume>33</volume><fpage>e13652</fpage><pub-id pub-id-type="doi">10.1111/ctr.13652</pub-id><pub-id pub-id-type="pmid">31230381</pub-id>
</element-citation></ref><ref id="B87-viruses-16-01884"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosemarie</surname><given-names>Q.</given-names></name>
<name><surname>Sugden</surname><given-names>B.</given-names></name>
</person-group><article-title>Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>1824</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8111824</pub-id><pub-id pub-id-type="pmid">33228078</pub-id>
</element-citation></ref><ref id="B88-viruses-16-01884"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lupo</surname><given-names>J.</given-names></name>
<name><surname>Wielandts</surname><given-names>A.S.</given-names></name>
<name><surname>Buisson</surname><given-names>M.</given-names></name>
<name><surname>Consortium</surname><given-names>C.</given-names></name>
<name><surname>Habib</surname><given-names>M.</given-names></name>
<name><surname>Hamoudi</surname><given-names>M.</given-names></name>
<name><surname>Morand</surname><given-names>P.</given-names></name>
<name><surname>Verduyn-Lunel</surname><given-names>F.</given-names></name>
<name><surname>Caillard</surname><given-names>S.</given-names></name>
<name><surname>Drouet</surname><given-names>E.</given-names></name>
</person-group><article-title>High Predictive Value of the Soluble ZEBRA Antigen (Epstein-Barr Virus Trans-Activator Zta) in Transplant Patients with PTLD</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><elocation-id>928</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11080928</pub-id><pub-id pub-id-type="pmid">36015048</pub-id>
</element-citation></ref><ref id="B89-viruses-16-01884"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>H.</given-names></name>
<name><surname>Gong</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Long</surname><given-names>J.</given-names></name>
<name><surname>Luo</surname><given-names>Q.</given-names></name>
<name><surname>Faleti</surname><given-names>O.D.</given-names></name>
<name><surname>Lyu</surname><given-names>X.</given-names></name>
</person-group><article-title>Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>164</volume><elocation-id>114916</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114916</pub-id><pub-id pub-id-type="pmid">37229802</pub-id>
</element-citation></ref><ref id="B90-viruses-16-01884"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bernhoff</surname><given-names>E.</given-names></name>
<name><surname>Gutteberg</surname><given-names>T.J.</given-names></name>
<name><surname>Sandvik</surname><given-names>K.</given-names></name>
<name><surname>Hirsch</surname><given-names>H.H.</given-names></name>
<name><surname>Rinaldo</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression</article-title><source>Am. J. Transplant.</source><year>2008</year><volume>8</volume><fpage>1413</fpage><lpage>1422</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2008.02269.x</pub-id><pub-id pub-id-type="pmid">18510636</pub-id>
</element-citation></ref><ref id="B91-viruses-16-01884"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kotton</surname><given-names>C.N.</given-names></name>
<name><surname>Kamar</surname><given-names>N.</given-names></name>
<name><surname>Wojciechowski</surname><given-names>D.</given-names></name>
<name><surname>Eder</surname><given-names>M.</given-names></name>
<name><surname>Hopfer</surname><given-names>H.</given-names></name>
<name><surname>Randhawa</surname><given-names>P.</given-names></name>
<name><surname>Sester</surname><given-names>M.</given-names></name>
<name><surname>Comoli</surname><given-names>P.</given-names></name>
<name><surname>Tedesco Silva</surname><given-names>H.</given-names></name>
<name><surname>Knoll</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation</article-title><source>Transplantation</source><year>2024</year><volume>108</volume><fpage>1834</fpage><lpage>1866</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000004976</pub-id><pub-id pub-id-type="pmid">38605438</pub-id>
</element-citation></ref><ref id="B92-viruses-16-01884"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knoll</surname><given-names>G.A.</given-names></name>
<name><surname>Humar</surname><given-names>A.</given-names></name>
<name><surname>Fergusson</surname><given-names>D.</given-names></name>
<name><surname>Johnston</surname><given-names>O.</given-names></name>
<name><surname>House</surname><given-names>A.A.</given-names></name>
<name><surname>Kim</surname><given-names>S.J.</given-names></name>
<name><surname>Ramsay</surname><given-names>T.</given-names></name>
<name><surname>Chasse</surname><given-names>M.</given-names></name>
<name><surname>Pang</surname><given-names>X.</given-names></name>
<name><surname>Zaltzman</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Levofloxacin for BK virus prophylaxis following kidney transplantation: A randomized clinical trial</article-title><source>JAMA</source><year>2014</year><volume>312</volume><fpage>2106</fpage><lpage>2114</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.14721</pub-id><pub-id pub-id-type="pmid">25399012</pub-id>
</element-citation></ref><ref id="B93-viruses-16-01884"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>S.J.</given-names></name>
<name><surname>Knight</surname><given-names>R.J.</given-names></name>
<name><surname>Kuten</surname><given-names>S.A.</given-names></name>
<name><surname>Graviss</surname><given-names>E.A.</given-names></name>
<name><surname>Nguyen</surname><given-names>D.T.</given-names></name>
<name><surname>Moore</surname><given-names>L.W.</given-names></name>
<name><surname>Musick</surname><given-names>W.L.</given-names></name>
<name><surname>Gaber</surname><given-names>A.O.</given-names></name>
</person-group><article-title>Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial</article-title><source>Am. J. Transplant.</source><year>2019</year><volume>19</volume><fpage>1831</fpage><lpage>1837</lpage><pub-id pub-id-type="doi">10.1111/ajt.15328</pub-id><pub-id pub-id-type="pmid">30811872</pub-id>
</element-citation></ref><ref id="B94-viruses-16-01884"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>T.R.</given-names></name>
<name><surname>Rao</surname><given-names>Z.S.</given-names></name>
<name><surname>Qiu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.P.</given-names></name>
<name><surname>Huang</surname><given-names>Z.L.</given-names></name>
<name><surname>Wang</surname><given-names>X.D.</given-names></name>
<name><surname>Lin</surname><given-names>T.</given-names></name>
</person-group><article-title>Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: A systematic review and meta-analysis</article-title><source>Kaohsiung J. Med. Sci.</source><year>2016</year><volume>32</volume><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.kjms.2016.01.004</pub-id><pub-id pub-id-type="pmid">27106006</pub-id>
</element-citation></ref><ref id="B95-viruses-16-01884"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Imlay</surname><given-names>H.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Leisenring</surname><given-names>W.M.</given-names></name>
<name><surname>Duke</surname><given-names>E.R.</given-names></name>
<name><surname>Kimball</surname><given-names>L.E.</given-names></name>
<name><surname>Huang</surname><given-names>M.L.</given-names></name>
<name><surname>Pergam</surname><given-names>S.A.</given-names></name>
<name><surname>Hill</surname><given-names>J.A.</given-names></name>
<name><surname>Jerome</surname><given-names>K.R.</given-names></name>
<name><surname>Milano</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation</article-title><source>Blood Adv.</source><year>2020</year><volume>4</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2019000802</pub-id><pub-id pub-id-type="pmid">32074279</pub-id>
</element-citation></ref><ref id="B96-viruses-16-01884"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seo</surname><given-names>S.K.</given-names></name>
<name><surname>Lo</surname><given-names>K.</given-names></name>
<name><surname>Abbo</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Current State of Antimicrobial Stewardship at Solid Organ and Hematopoietic Cell Transplant Centers in the United States</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2016</year><volume>37</volume><fpage>1195</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1017/ice.2016.149</pub-id><pub-id pub-id-type="pmid">27457099</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="viruses-16-01884-t001"><object-id pub-id-type="pii">viruses-16-01884-t001_Table 1</object-id><label>Table 1</label><caption><p>Antiviral stewardship challenges and opportunities in cytomegalovirus in solid organ transplantation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Focus Area </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Challenges</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opportunities</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-emptive therapy (PET)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">vGCV prophylaxis most common strategy.<break/>PET is resource-intensive.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PET personalized therapy, improved CMV, immunologic, mortality endpoints vs. prophylaxis in high-risk liver transplant. </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Letermovir<break/>prophylaxis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited evidence outside of kidney transplant.<break/>Cost, availability, drug interactions.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prophylaxis targeted to groups intolerant of vGCV, cytopenias.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secondary prophylaxis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recurrent DNAemia/disease may occur after therapy cessation.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secondary prophylaxis should be avoided generally.<break/>Consider for high-risk patients with severe disease.<break/>CMI monitoring may be helpful.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug administration</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate&#x02013;severe disease may require hospitalization.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV to oral transition should be performed in most scenarios.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Therapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">vGCV/GCV with myelosuppressive effects, renal dose adjustment.<break/>Foscarnet with nephrotoxicity, electrolyte wasting.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maribavir less myelosuppressive and nephrotoxic.<break/>Consider for R/R disease, GCV intolerance, and cytopenias.</td></tr></tbody></table><table-wrap-foot><fn><p>PET: pre-emptive therapy; vGCV: valganciclovir; GCV: ganciclovir; CMI: cell-mediated immunity; R/R: refractory/resistant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01884-t002"><object-id pub-id-type="pii">viruses-16-01884-t002_Table 2</object-id><label>Table 2</label><caption><p>Antiviral stewardship challenges and opportunities in cytomegalovirus in allogeneic hematopoietic cell transplantation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Focus Area</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Challenges</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opportunities</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Letermovir<break/>prophylaxis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delays CMV-CMI with late-stage reactivation.<break/>Cost, availability, drug interactions.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prophylaxis targeted to groups with high risk of CMV infection.<break/>Duration of prophylaxis guided by CMV-CMI.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug administration</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral vGCV absorption in setting of gastrointestinal disease and GVHD.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transition from intravenous to oral therapy with GVHD stage <inline-formula><mml:math id="mm4" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02264;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Therapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">vGCV and GCV with myelosuppressive effects, requires renal dose adjustment. <break/>Foscarnet with nephrotoxicity, electrolyte wasting.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maribavir less myelosuppressive and nephrotoxic.<break/>CTLs may restore CMV-CMI and prevent late-stage reactivation; role in AVS needs further definition.</td></tr></tbody></table><table-wrap-foot><fn><p>CMV-CMI: cytomegalovirus T-cell-mediated immunity; GVHD: graft-versus-host disease; CTL: CMV-specific T-cells.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01884-t003"><object-id pub-id-type="pii">viruses-16-01884-t003_Table 3</object-id><label>Table 3</label><caption><p>Antiviral stewardship challenges and opportunities in respiratory syncytial virus.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Area</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Challenges</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opportunities</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rapid diagnostics</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ribavirin therapy less effective at LRD stage.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical treatment guideline for alloHCT/lung transplant presenting with URI symptoms with prompt testing using multiplex PCR respiratory viral panel.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted treatment</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimal benefit of ribavirin in low- and moderate-risk ISI-RSV patients.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment algorithm reserving ribavirin treatment for alloHCT/lung transplant with high-risk patients ISI-RSV.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug administration</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toxicity of nebulized ribavirin to patients and healthcare providers.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replace aerosolized with oral ribavirin in adult hospital formularies.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lack of efficacy data on immunocompromised hosts.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shared clinical decision making during pre-SOT and HCT evaluations.</td></tr></tbody></table><table-wrap-foot><fn><p>LRD: lower respiratory tract disease; URI: upper respiratory tract; PCR: polymerase chain reaction; ISI: Immunodeficiency Scoring Index; SOT: solid organ transplant; HCT: hematopoietic cell transplant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01884-t004"><object-id pub-id-type="pii">viruses-16-01884-t004_Table 4</object-id><label>Table 4</label><caption><p>Antiviral stewardship challenges and opportunities in SARS-CoV-2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Area</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Challenges</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opportunities</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rapid diagnostics</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 NP swab screening of asymptomatic patients may lead to over treatment. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diagnostic stewardship limiting SARS-CoV-2 screening in asymptomatic patients in the pre- and post-transplant setting.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted treatment</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unclear benefit of therapy in asymptomatic or mildly symptomatic patients.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment algorithm reserving treatment for patients with significant symptoms who are high risk.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug administration</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remdesivir must be given intravenously.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Appropriate durations of remdesivir based on disease severity (3 days mild&#x02013;moderate; 5 days severe).</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug&#x02013;drug interaction</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nirmatrelvir&#x02013;ritonavir strong inhibitor of cytochrome P450 3A4, causing CNI interaction.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Educate patients and providers to avoid CNIs in SOT recipients unless close monitoring available.</td></tr></tbody></table><table-wrap-foot><fn><p>NP: nasopharyngeal; SOT: solid organ transplant; CNI: calcineurin inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01884-t005"><object-id pub-id-type="pii">viruses-16-01884-t005_Table 5</object-id><label>Table 5</label><caption><p>Antiviral stewardship challenges and opportunities in EBV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Area</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Challenges</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Opportunities</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diagnostics</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBV DNAemia recommended in high-risk patients, no defined threshold for preemptive interventions.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Institutional protocol for EBV DNA monitoring and threshold validation.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Management</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For EBV DNAemia: RIS primary strategy in SOT; rituximab primary in HCT.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monitor appropriateness of rituximab therapy in HCT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antivirals</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antivirals (ACV, GCV) with in vitro activity; limited evidence for prevention or treatment of EBV/PTLD.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monitor antivirals used to treat EBV/PTLD.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cellular therapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBV CTLs recommended in HCT, not SOT.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">If available, institutional protocol for CTLs; role in AVS needs further definition.</td></tr></tbody></table><table-wrap-foot><fn><p>EBV: Epstein&#x02013;Barr virus; RIS: reduction in immunosuppression; HCT: hematopoietic cell transplant; SOT: Solid organ transplantation; ACV: acyclovir; GCV: ganciclovir; CTLs: EBV-specific T-cells; AVS: antiviral stewardship.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01884-t006"><object-id pub-id-type="pii">viruses-16-01884-t006_Table 6</object-id><label>Table 6</label><caption><p>Examples of potential antiviral stewardship program metrics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Process</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Balancing</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Usage (DOT, LOT)<break/><break/>Guideline adherence<break/><break/>Intervention acceptance rate<break/><break/>Diagnostic appropriateness (CMV PCR, CMI testing)<break/><break/><break/><break/></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infection rate: <break/>CMV DNAemia and disease.<break/><break/>Virus-related hospitalization.<break/><break/>Adverse drug event.<break/><break/>Resistance rate.<break/><break/>Time to CMV eradication.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infection rate.<break/><break/>Virus-related readmission.<break/><break/>Readmission.<break/><break/>Recurrent DNAemia/disease after treatment.<break/><break/>Infectious mortality (CMV/RSV).</td></tr></tbody></table><table-wrap-foot><fn><p>DOT: days of therapy; LOT: length of therapy; CMI: cell-mediated immunity.</p></fn></table-wrap-foot></table-wrap></floats-group></article>